SalemExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|-------------|------------|-----|---------------------|------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 22.80 | 31 | 136 | Male | 16.66 | 16 | 96 |
| Female | 10.30 | 6 | 58 | Female | 15.18 | 17 | 112 |
| Total | 33.10 | 37 | 112 | Total | 31.84 | 33 | 104 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 7.64 | 6 | 79 | Male | 4.63 | 4 | NC* |
| Female | 7.27 | 4 | NC* | Female | 4.98 | 7 | 141 |
| Total | 14.91 | 10 | 67 | Total | 9.60 | 11 | 115 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma_ | | |
| Male | 1.12 | 2 | NC* | Male | 19.13 | 19 | 99 |
| Female | 164.09 | 177 | 108 | Female | 20.04 | 21 | 105 |
| Total | 165.21 | 179 | 108 | Total | 39.17 | 40 | 102 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>/nx</u> | | |
| | | | | Male | 14.21 | 23 | 162 #+ |
| Female | 9.34 | 6 | 64 | Female | 8.23 | 13 | 158 |
| | | | | Total | 22.44 | 36 | 160 #+ |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 57.26 | 60 | 105 | | | | |
| Female | 67.96 | 69 | 102 | Female | 19.25 | 29 | 151 #+ |
| Total | 125.22 | 129 | 103 | | | | |
| <u>Esophagus</u> | | | | Pancreas Pancreas | | | |
| Male | 8.24 | 13 | 158 | Male | 10.14 | 14 | 138 |
| Female | 3.18 | 5 | 157 | Female | 13.14 | 14 | 107 |
| Total | 11.43 | 18 | 157 | Total | 23.28 | 28 | 120 |
| Hodgkin's Disease (| | | | <u>Prostate</u> | | | |
| Male | 3.82 | 5 | 131 | Male | 143.07 | 185 | 129 ^+ |
| Female | 3.62 | 5 | 138 | | | | |
| Total | 7.44 | 10 | 134 | | | | |
| Kidney & Renal Pelv | | | | <u>Stomach</u> | | | |
| Male | 13.77 | 21 | 153 | Male | 10.00 | 8 | 80 |
| Female | 9.87 | 9 | 91 | Female | 7.47 | 6 | 80 |
| Total | 23.64 | 30 | 127 | Total | 17.47 | 14 | 80 |
| <u>Larynx</u> | 20.0 | | | <u>Testis</u> | | | |
| Male | 7.34 | 6 | 82 | Male | 6.50 | 7 | 108 |
| Female | 2.13 | 3 | NC* | maio | 0.00 | • | 100 |
| Total | 9.47 | 9 | 95 | | | | |
| <u>Leukemia</u> | 0.17 | v | 00 | <u>Thyroid</u> | | | |
| Male | 11.63 | 15 | 129 | Male | 3.45 | 6 | 174 |
| Female | 10.91 | 10 | 92 | Female | 11.41 | 4 | NC* |
| Total | 22.54 | 25 | 111 | Total | 14.86 | 10 | 67 |
| Liver and Intrahepa | | 20 | 111 | Uteri, Corpus and L | | 10 | 01 |
| Male | 5.89 | 4 | NC* | oten, corpus and t | norus, NOS | | |
| Female | 2.88 | 1 | NC* | Eamala | 30.42 | 26 | 118 |
| | | · | | Female | 30.42 | 36 | 110 |
| Total | 8.78 | 5 | 57 | | | | |

| Lung and Bronchus | | | | All Sites / Types | | | |
|-------------------|--------|-----|--------|-------------------|---------|------|--------|
| Male | 72.00 | 103 | 143 ^+ | Male | 471.25 | 575 | 122 ^+ |
| Female | 70.06 | 108 | 154 ^+ | Female | 531.73 | 593 | 112 ~+ |
| Total | 142.06 | 211 | 149 ^+ | Total | 1002.98 | 1168 | 116 ^+ |

SalisburyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|--------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.12 | 2 | NC* | Male | 3.20 | 3 | NC* |
| Female | 1.48 | 1 | NC* | Female | 2.47 | 6 | 243 |
| Total | 5.60 | 3 | NC* | Total | 5.66 | 9 | 159 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 1.48 | 2 | NC* | Male | 0.88 | 1 | NC* |
| Female | 1.18 | 0 | NC* | Female | 0.76 | 1 | NC* |
| Total | 2.67 | 2 | NC* | Total | 1.64 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.21 | 0 | NC* | Male | 3.57 | 1 | NC* |
| Female | 27.78 | 32 | 115 | Female | 3.06 | 2 | NC* |
| Total | 27.99 | 32 | 114 | Total | 6.63 | 3 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>'nx</u> | | |
| | | | | Male | 2.87 | 2 | NC* |
| Female | 1.53 | 3 | NC* | Female | 1.33 | 1 | NC* |
| | | | | Total | 4.20 | 3 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.48 | 23 | 220 ~+ | | | | |
| Female | 9.62 | 13 | 135 | Female | 3.21 | 5 | 156 |
| Total | 20.10 | 36 | 179 ~+ | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.62 | 5 | 309 | Male | 1.90 | 2 | NC* |
| Female | 0.46 | 0 | NC* | Female | 1.88 | 3 | NC* |
| Total | 2.07 | 5 | 241 | Total | 3.78 | 5 | 132 |
| Hodgkin's Disease (I | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.68 | 2 | NC* | Male | 28.28 | 30 | 106 |
| Female | 0.57 | 0 | NC* | | | | |
| Total | 1.25 | 2 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |
| Male | 2.70 | 3 | NC* | Male | 1.82 | 1 | NC* |
| Female | 1.61 | 6 | 373 #+ | Female | 1.04 | 3 | NC* |
| Total | 4.31 | 9 | 209 | Total | 2.86 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.49 | 4 | NC* | Male | 1.06 | 2 | NC* |
| Female | 0.37 | 0 | NC* | | | | |
| Total | 1.86 | 4 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.18 | 1 | NC* | Male | 0.66 | 1 | NC* |
| Female | 1.70 | 3 | NC* | Female | 1.87 | 2 | NC* |

| Total | 3.88 | 4 | NC* | Total | 2.53 | 3 | NC* | |
|----------------------|---------------|----|--------|-------------------------------|--------|-----|---------|--|
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 1.17 | 1 | NC* | | | | | |
| Female | 0.42 | 0 | NC* | Female | 5.30 | 8 | 151 | |
| Total | 1.59 | 1 | NC* | | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | | |
| Male | 13.74 | 20 | 146 | Male | 89.88 | 115 | 128 #+ | |
| Female | 11.27 | 18 | 160 | Female | 84.78 | 111 | 131 ~+> | |
| Total | 25 01 | 38 | 152 #+ | Total | 174 66 | 226 | 129 ^+ | |

Sandisfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|------------|------------|-----|----------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.79 | 1 | NC* | Male | 0.52 | 0 | NC* |
| Female | 0.21 | 0 | NC* | Female | 0.28 | 0 | NC* |
| Total | 0.99 | 1 | NC* | Total | 0.80 | 0 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.23 | 0 | NC* | Male | 0.16 | 0 | NC* |
| Female | 0.14 | 0 | NC* | Female | 0.10 | 1 | NC* |
| Total | 0.36 | 0 | NC* | Total | 0.26 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.04 | 0 | NC* | Male | 0.59 | 2 | NC* |
| Female | 3.32 | 5 | 151 | Female | 0.40 | 0 | NC* |
| Total | 3.36 | 5 | 149 | Total | 0.99 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>1X</u> | | |
| | | | | Male | 0.48 | 0 | NC* |
| Female | 0.16 | 0 | NC* | Female | 0.17 | 1 | NC* |
| | | | | Total | 0.65 | 1 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.99 | 1 | NC* | | | | |
| Female | 1.33 | 0 | NC* | Female | 0.38 | 1 | NC* |
| Total | 3.32 | 1 | NC* | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 0.30 | 1 | NC* | Male | 0.35 | 0 | NC* |
| Female | 0.06 | 0 | NC* | Female | 0.27 | 0 | NC* |
| Total | 0.36 | 1 | NC* | Total | 0.62 | 0 | NC* |
| Hodgkin's Disease (H | | oma) | | <u>Prostate</u> | | | |
| Male | 0.08 | 0 | NC* | Male | 5.45 | 2 | NC* |
| Female | 0.06 | 0 | NC* | | | | |
| Total | 0.14 | 0 | NC* | | | | |
| Kidney & Renal Pelvi | | | | <u>Stomach</u> | | | |
| Male | 0.46 | 0 | NC* | Male | 0.34 | 0 | NC* |
| Female | 0.21 | 0 | NC* | Female | 0.14 | 0 | NC* |
| Total | 0.67 | 0 | NC* | Total | 0.48 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.27 | 1 | NC* | Male | 0.11 | 0 | NC* |

| Female | 0.05 | 0 | NC* | | | | |
|-----------------------|--------------|---|-----|---------------------|------------|----|-------|
| Total | 0.31 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.36 | 0 | NC* | Male | 0.09 | 0 | NC* |
| Female | 0.21 | 0 | NC* | Female | 0.18 | 0 | NC* |
| Total | 0.57 | 0 | NC* | Total | 0.27 | 0 | NC* |
| Liver and Intrahepati | c Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 0.20 | 0 | NC* | | | | |
| Female | 0.06 | 0 | NC* | Female | 0.65 | 1 | NC* |
| Total | 0.26 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 2.63 | 1 | NC* | Male | 16.43 | 9 | 55 > |
| Female | 1.52 | 1 | NC* | Female | 10.64 | 11 | 103 > |
| Total | 4.15 | 2 | NC* | Total | 27.08 | 20 | 74 > |

Sandwich
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|------------|---------------------|------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 14.64 | 15 | 102 | Male | 10.02 | 19 | 190 #+ |
| Female | 5.01 | 8 | 160 | Female | 7.23 | 15 | 207 #+ |
| Total | 19.65 | 23 | 117 | Total | 17.26 | 34 | 197 ^+ |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 4.48 | 4 | NC* | Male | 2.98 | 3 | NC* |
| Female | 3.57 | 6 | 168 | Female | 2.51 | 1 | NC* |
| Total | 8.05 | 10 | 124 | Total | 5.49 | 4 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.71 | 0 | NC* | Male | 11.46 | 9 | 79 |
| Female | 84.46 | 86 | 102 | Female | 9.82 | 6 | 61 |
| Total | 85.18 | 86 | 101 | Total | 21.28 | 15 | 70 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 8.95 | 8 | 89 |
| Female | 4.25 | 3 | NC* | Female | 4.18 | 7 | 167 |
| | | | | Total | 13.14 | 15 | 114 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 36.55 | 37 | 101 | | | | |
| Female | 32.85 | 36 | 110 | Female | 9.68 | 9 | 93 |
| Total | 69.40 | 73 | 105 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 5.32 | 5 | 94 | Male | 6.50 | 3 | NC* |
| Female | 1.55 | 3 | NC* | Female | 6.40 | 6 | 94 |
| Total | 6.88 | 8 | 116 | Total | 12.90 | 9 | 70 |
| Hodgkin's Disease (I | Hodgkin Lympho | oma) | | Prostate | | | |
| Male | 1.81 | 0 | NC* | Male | 93.52 | 110 | 118 |
| Female | 1.52 | 1 | NC* | | | | |
| Total | 3.33 | 1 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |

| Male | 8.73 | 6 | 69 | Male | 6.35 | 6 | 95 |
|----------------------|----------------|----|-------|---------------------|-------------|-----|-----|
| Female | 5.05 | 5 | 99 | Female | 3.52 | 3 | NC* |
| Total | 13.77 | 11 | 80 | Total | 9.87 | 9 | 91 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 4.75 | 3 | NC* | Male | 2.53 | 1 | NC* |
| Female | 1.16 | 1 | NC* | | | | |
| Total | 5.91 | 4 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 7.15 | 11 | 154 | Male | 1.83 | 1 | NC* |
| Female | 5.36 | 7 | 130 | Female | 5.00 | 8 | 160 |
| Total | 12.52 | 18 | 144 | Total | 6.83 | 9 | 132 |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and L | Jterus, NOS | | |
| Male | 3.75 | 1 | NC* | | | | |
| Female | 1.41 | 0 | NC* | Female | 16.28 | 10 | 61 |
| Total | 5.16 | 1 | NC* | | | | |
| Lung and Bronchus | į | | | All Sites / Types | | | |
| Male | 46.48 | 31 | 67 #- | Male | 298.02 | 295 | 99 |
| Female | 36.38 | 36 | 99 | Female | 266.49 | 278 | 104 |
| Total | 82.86 | 67 | 81 | Total | 564.51 | 573 | 102 |

Saugus
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Ехр | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|--------------|------------|-----|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 19.30 | 28 | 145 | Male | 13.27 | 13 | 98 |
| Female | 7.46 | 8 | 107 | Female | 10.40 | 9 | 87 |
| Total | 26.76 | 36 | 135 | Total | 23.67 | 22 | 93 |
| Brain and Other Ner | rvous System | | | Multiple Myeloma | | | |
| Male | 5.87 | 9 | 153 | Male | 3.93 | 1 | NC* |
| Female | 5.02 | 3 | NC* | Female | 3.68 | 4 | NC* |
| Total | 10.89 | 12 | 110 | Total | 7.61 | 5 | 66 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.95 | 1 | NC* | Male | 15.16 | 21 | 138 |
| Female | 120.61 | 109 | 90 | Female | 14.35 | 12 | 84 |
| Total | 121.56 | 110 | 90 | Total | 29.51 | 33 | 112 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 11.73 | 12 | 102 |
| Female | 6.09 | 7 | 115 | Female | 6.04 | 8 | 132 |
| | | | | Total | 17.77 | 20 | 113 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 48.36 | 51 | 105 | | | | |
| Female | 48.72 | 52 | 107 | Female | 13.89 | 9 | 65 |
| Total | 97.08 | 103 | 106 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 7.05 | 8 | 113 | Male | 8.55 | 11 | 129 |
| Female | 2.31 | 1 | NC* | Female | 9.54 | 6 | 63 |
| Total | 9.36 | 9 | 96 | Total | 18.09 | 17 | 94 |

| Hodgkin's Disease | (Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
|---------------------|-----------------|------|-----|---------------------|-------------|-----|--------|
| Male | 2.48 | 0 | NC* | Male | 125.31 | 143 | 114 |
| Female | 2.17 | 3 | NC* | | | | |
| Total | 4.65 | 3 | NC* | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | <u>Stomach</u> | | | |
| Male | 11.48 | 14 | 122 | Male | 8.30 | 10 | 120 |
| Female | 7.32 | 8 | 109 | Female | 5.27 | 5 | 95 |
| Total | 18.79 | 22 | 117 | Total | 13.58 | 15 | 110 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 6.29 | 5 | 80 | Male | 3.73 | 7 | 188 |
| Female | 1.67 | 2 | NC* | | | | |
| Total | 7.96 | 7 | 88 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 9.28 | 14 | 151 | Male | 2.48 | 5 | 201 |
| Female | 7.65 | 10 | 131 | Female | 7.13 | 9 | 126 |
| Total | 16.93 | 24 | 142 | Total | 9.61 | 14 | 146 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and U | Jterus, NOS | | |
| Male | 4.94 | 9 | 182 | | | | |
| Female | 2.08 | 3 | NC* | Female | 23.15 | 23 | 99 |
| Total | 7.02 | 12 | 171 | | | | |
| Lung and Bronchus | <u> </u> | | | All Sites / Types | | | |
| Male | 62.18 | 65 | 105 | Male | 396.31 | 457 | 115 ~+ |
| Female | 53.09 | 59 | 111 | Female | 385.86 | 372 | 96 |
| Total | 115.27 | 124 | 108 | Total | 782.18 | 829 | 106 |

SavoyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | SIR |
|----------------------|------------|------------|-----|----------------------|-----------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.45 | 1 | NC* | Male | 0.34 | 0 | NC* |
| Female | 0.13 | 0 | NC* | Female | 0.22 | 0 | NC* |
| Total | 0.59 | 1 | NC* | Total | 0.56 | 0 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.15 | 0 | NC* | Male | 0.09 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.07 | 1 | NC* |
| Total | 0.26 | 0 | NC* | Total | 0.16 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.02 | 0 | NC* | Male | 0.38 | 0 | NC* |
| Female | 2.56 | 3 | NC* | Female | 0.28 | 0 | NC* |
| Total | 2.58 | 3 | NC* | Total | 0.66 | 0 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>1X</u> | | |
| | | | | Male | 0.30 | 0 | NC* |
| Female | 0.14 | 0 | NC* | Female | 0.12 | 0 | NC* |
| | | | | Total | 0.42 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.14 | 2 | NC* | | | | |
| Female | 0.87 | 0 | NC* | Female | 0.29 | 0 | NC* |

| Total | 2.01 | 2 | NC* | | | | |
|--------------------------|-----------------|------------|-----|---------------------|------------|----|-------|
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.17 | 0 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.04 | 0 | NC* | Female | 0.17 | 0 | NC* |
| Total | 0.21 | 0 | NC* | Total | 0.38 | 0 | NC* |
| Hodgkin's Disease (I | Hodgkin Lymphor | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 0.07 | 0 | NC* | Male | 3.00 | 1 | NC* |
| Female | 0.05 | 0 | NC* | | | | |
| Total | 0.11 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | Stomach . | | | |
| Male | 0.29 | 0 | NC* | Male | 0.20 | 0 | NC* |
| Female | 0.15 | 0 | NC* | Female | 0.09 | 0 | NC* |
| Total | 0.43 | 0 | NC* | Total | 0.29 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.16 | 0 | NC* | Male | 0.10 | 0 | NC* |
| Female | 0.03 | 0 | NC* | | | | |
| Total | 0.19 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.23 | 0 | NC* | Male | 0.07 | 0 | NC* |
| Female | 0.15 | 1 | NC* | Female | 0.16 | 0 | NC* |
| Total | 0.38 | 1 | NC* | Total | 0.23 | 0 | NC* |
| Liver and Intrahepati | ic Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 0.12 | 2 | NC* | | | | |
| Female | 0.04 | 0 | NC* | Female | 0.49 | 2 | NC* |
| Total | 0.16 | 2 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 1.47 | 0 | NC* | Male | 9.58 | 6 | 63 > |
| Female | 1.05 | 1 | NC* | Female | 7.74 | 8 | 103 > |
| Total | 2.52 | 1 | NC* | Total | 17.32 | 14 | 81 > |

ScituateExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 11.97 | 10 | 84 | Male | 8.47 | 14 | 165 |
| Female | 4.42 | 6 | 136 | Female | 6.48 | 6 | 93 |
| Total | 16.39 | 16 | 98 | Total | 14.95 | 20 | 134 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 3.79 | 3 | NC* | Male | 2.48 | 0 | NC* |
| Female | 3.14 | 4 | NC* | Female | 2.22 | 1 | NC* |
| Total | 6.94 | 7 | 101 | Total | 4.69 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>nphoma</u> | | |
| Male | 0.60 | 1 | NC* | Male | 9.57 | 11 | 115 |
| Female | 75.60 | 86 | 114 | Female | 8.67 | 10 | 115 |
| Total | 76.20 | 87 | 114 | Total | 18.24 | 21 | 115 |
| Cervix Uteri | | | | Oral Cavity & Pharys | <u>nx</u> | | |
| | | | | Male | 7.67 | 11 | 143 |

| Female | 3.83 | 2 | NC* | Female | 3.72 | 11 | 295 ~+ |
|----------------------|----------------|------------|-----|---------------------|--------------------|-----|--------|
| Tomalo | 0.00 | - | | Total | 11.39 | 22 | 193 ~+ |
| Colon / Rectum | | | | <u>Ovary</u> | 11.00 | | 100 |
| Male | 30.17 | 23 | 76 | | | | |
| Female | 28.74 | 23 | 80 | Female | 8.67 | 6 | 69 |
| Total | 58.91 | 46 | 78 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 4.53 | 1 | NC* | Male | 5.39 | 4 | NC* |
| Female | 1.37 | 0 | NC* | Female | 5.63 | 8 | 142 |
| Total | 5.89 | 1 | NC* | Total | 11.02 | 12 | 109 |
| Hodgkin's Disease (| Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 1.56 | 0 | NC* | Male | 80.46 | 80 | 99 |
| Female | 1.36 | 0 | NC* | | | | |
| Total | 2.91 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>vis</u> | | | Stomach | | | |
| Male | 7.36 | 7 | 95 | Male | 5.20 | 1 | NC* |
| Female | 4.50 | 2 | NC* | Female | 3.10 | 1 | NC* |
| Total | 11.86 | 9 | 76 | Total | 8.30 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 4.08 | 4 | NC* | Male | 2.23 | 1 | NC* |
| Female | 1.04 | 3 | NC* | | | | |
| Total | 5.13 | 7 | 137 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 5.88 | 7 | 119 | Male | 1.60 | 1 | NC* |
| Female | 4.72 | 9 | 191 | Female | 4.51 | 3 | NC* |
| Total | 10.60 | 16 | 151 | Total | 6.11 | 4 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and L | <u>Jterus, NOS</u> | | |
| Male | 3.18 | 3 | NC* | | | | |
| Female | 1.24 | 1 | NC* | Female | 14.59 | 14 | 96 |
| Total | 4.42 | 4 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 39.24 | 38 | 97 | Male | 251.42 | 237 | 94 |
| Female | 32.34 | 38 | 118 | Female | 236.81 | 247 | 104 |
| Total | 71.58 | 76 | 106 | Total | 488.23 | 484 | 99 |

Seekonk
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|-----|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 10.10 | 10 | 99 | Male | 7.28 | 6 | 82 |
| Female | 3.47 | 1 | NC* | Female | 5.33 | 4 | NC* |
| Total | 13.56 | 11 | 81 | Total | 12.61 | 10 | 79 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 3.24 | 5 | 154 | Male | 2.10 | 1 | NC* |
| Female | 2.54 | 3 | NC* | Female | 1.77 | 2 | NC* |
| Total | 5.78 | 8 | 138 | Total | 3.86 | 3 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |

| Male | 0.51 | 1 | NC* | Male | 8.18 | 3 | NC* |
|---------------------|-----------------|------------|-------|---------------------|-------------|-----|--------|
| Female | 62.13 | 65 | 105 | Female | 6.92 | 5 | 72 |
| Total | 62.64 | 66 | 105 | Total | 15.10 | 8 | 53 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>ynx</u> | | |
| | | | | Male | 6.61 | 7 | 106 |
| Female | 3.20 | 1 | NC* | Female | 3.01 | 0 | NC* |
| | | | | Total | 9.62 | 7 | 73 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 25.50 | 23 | 90 | | | | |
| Female | 22.55 | 25 | 111 | Female | 7.10 | 9 | 127 |
| Total | 48.06 | 48 | 100 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 3.86 | 2 | NC* | Male | 4.58 | 2 | NC* |
| Female | 1.07 | 1 | NC* | Female | 4.40 | 1 | NC* |
| Total | 4.93 | 3 | NC* | Total | 8.98 | 3 | NC* |
| Hodgkin's Disease | (Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 1.36 | 0 | NC* | Male | 68.23 | 51 | 75 #- |
| Female | 1.11 | 1 | NC* | | | | |
| Total | 2.47 | 1 | NC* | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | Stomach | | | |
| Male | 6.28 | 5 | 80 | Male | 4.42 | 11 | 249 #+ |
| Female | 3.63 | 0 | NC* | Female | 2.42 | 0 | NC* |
| Total | 9.91 | 5 | 50 | Total | 6.84 | 11 | 161 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 3.49 | 2 | NC* | Male | 1.97 | 3 | NC* |
| Female | 0.85 | 0 | NC* | | | | |
| Total | 4.34 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | Thyroid | | | |
| Male | 4.97 | 4 | NC* | Male | 1.40 | 1 | NC* |
| Female | 3.76 | 5 | 133 | Female | 3.79 | 4 | NC* |
| Total | 8.73 | 9 | 103 | Total | 5.19 | 5 | 96 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and L | Jterus, NOS | | |
| Male | 2.72 | 1 | NC* | | | | |
| Female | 0.98 | 1 | NC* | Female | 11.99 | 7 | 58 |
| Total | 3.69 | 2 | NC* | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 33.14 | 17 | 51 ~- | Male | 213.50 | 164 | 77 ^- |
| Female | 25.91 | 15 | 58 #- | Female | 191.37 | 160 | 84 #- |
| Total | 59.05 | 32 | 54 ^- | Total | 404.86 | 324 | 80 ^- |
| | | | | | | | |

Sharon

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|------------------|------------|------------|-----|------------------|------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 11.51 | 11 | 96 | Male | 8.60 | 10 | 116 |
| Female | 3.86 | 3 | NC* | Female | 6.16 | 12 | 195 #+ |
| Total | 15.37 | 14 | 91 | Total | 14.76 | 22 | 149 |

| Brain and Other Ne | rvous System | | | Multiple Myeloma | | | |
|---------------------|-----------------|-------------|-------|---------------------|-------------|-----|--------|
| Male | 3.88 | 3 | NC* | Male | 2.44 | 4 | NC* |
| Female | 2.95 | 5 | 169 | Female | 2.01 | 2 | NC* |
| Total | 6.83 | 8 | 117 | Total | 4.45 | 6 | 135 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | /mphoma | | |
| Male | 0.59 | 0 | NC* | Male | 9.53 | 15 | 157 |
| Female | 73.01 | 85 | 116 | Female | 7.81 | 13 | 166 |
| Total | 73.60 | 85 | 115 | Total | 17.34 | 28 | 161 #+ |
| Cervix Uteri | | | | Oral Cavity & Phar | <u>ynx</u> | | |
| | | | | Male | 7.99 | 5 | 63 |
| Female | 3.69 | 3 | NC* | Female | 3.49 | 1 | NC* |
| | | | | Total | 11.48 | 6 | 52 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 29.20 | 28 | 96 | | | | |
| Female | 24.99 | 21 | 84 | Female | 8.28 | 10 | 121 |
| Total | 54.19 | 49 | 90 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 4.55 | 2 | NC* | Male | 5.32 | 8 | 150 |
| Female | 1.20 | 3 | NC* | Female | 4.88 | 2 | NC* |
| Total | 5.74 | 5 | 87 | Total | 10.20 | 10 | 98 |
| Hodgkin's Disease | (Hodgkin Lympho | ma <u>)</u> | | <u>Prostate</u> | | | |
| Male | 1.57 | 1 | NC* | Male | 80.01 | 62 | 77 #- |
| Female | 1.25 | 1 | NC* | | | | |
| Total | 2.82 | 2 | NC* | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | Stomach | | | |
| Male | 7.47 | 5 | 67 | Male | 5.09 | 5 | 98 |
| Female | 4.19 | 3 | NC* | Female | 2.69 | 7 | 260 #+ |
| Total | 11.66 | 8 | 69 | Total | 7.78 | 12 | 154 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 4.18 | 2 | NC* | Male | 2.12 | 2 | NC* |
| Female | 1.00 | 0 | NC* | | | | |
| Total | 5.18 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 5.86 | 5 | 85 | Male | 1.65 | 6 | 363 #+ |
| Female | 4.36 | 2 | NC* | Female | 4.37 | 14 | 321 ^+ |
| Total | 10.22 | 7 | 68 | Total | 6.02 | 20 | 332 ^+ |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and I | Uterus, NOS | | |
| Male | 3.24 | 2 | NC* | | | | |
| Female | 1.09 | 1 | NC* | Female | 14.21 | 10 | 70 |
| Total | 4.33 | 3 | NC* | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 38.35 | 30 | 78 | Male | 248.75 | 213 | 86 #- |
| Female | 29.60 | 19 | 64 | Female | 220.25 | 227 | 103 |
| Total | 67.95 | 49 | 72 #- | Total | 469.00 | 440 | 94 |
| | | | | | | | |

Sheffield

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|----------------|------------|------------|----------------------|---------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 2.45 | 0 | NC* | Male | 1.70 | 0 | NC* |
| Female | 0.82 | 0 | NC* | Female | 1.22 | 0 | NC* |
| Total | 3.27 | 0 | NC* | Total | 2.92 | 0 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.76 | 3 | NC* | Male | 0.50 | 1 | NC* |
| Female | 0.59 | 0 | NC* | Female | 0.41 | 0 | NC* |
| Total | 1.35 | 3 | NC* | Total | 0.91 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>mphoma</u> | | |
| Male | 0.12 | 0 | NC* | Male | 1.94 | 2 | NC* |
| Female | 14.08 | 6 | 43 #- | Female | 1.62 | 0 | NC* |
| Total | 14.20 | 6 | 42 #- | Total | 3.56 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 1.54 | 4 | NC* |
| Female | 0.73 | 0 | NC* | Female | 0.69 | 0 | NC* |
| | | | | Total | 2.23 | 4 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 6.15 | 9 | 146 | | | | |
| Female | 5.37 | 7 | 130 | Female | 1.62 | 1 | NC* |
| Total | 11.52 | 16 | 139 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 0.91 | 0 | NC* | Male | 1.10 | 2 | NC* |
| Female | 0.25 | 0 | NC* | Female | 1.05 | 2 | NC* |
| Total | 1.16 | 0 | NC* | Total | 2.15 | 4 | NC* |
| Hodgkin's Disease (H | lodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.31 | 1 | NC* | Male | 16.01 | 21 | 131 |
| Female | 0.26 | 0 | NC* | | | | |
| Total | 0.58 | 1 | NC* | | | | |
| Kidney & Renal Pelvis | <u>s</u> | | | <u>Stomach</u> | | | |
| Male | 1.47 | 2 | NC* | Male | 1.07 | 0 | NC* |
| Female | 0.84 | 0 | NC* | Female | 0.58 | 1 | NC* |
| Total | 2.31 | 2 | NC* | Total | 1.65 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.81 | 3 | NC* | Male | 0.45 | 1 | NC* |
| Female | 0.19 | 0 | NC* | | | | |
| Total | 1.00 | 3 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 1.19 | 2 | NC* | Male | 0.32 | 1 | NC* |
| Female | 0.88 | 0 | NC* | Female | 0.86 | 1 | NC* |
| Total | 2.07 | 2 | NC* | Total | 1.18 | 2 | NC* |
| Liver and Intrahepation | Bile Ducts | | | Uteri, Corpus and Ut | terus, NOS | | |
| Male | 0.63 | 0 | NC* | | | | |
| Female | 0.23 | 0 | NC* | Female | 2.70 | 2 | NC* |
| Total | 0.87 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 7.85 | 8 | 102 | Male | 50.55 | 62 | 123 > |
| | | | | | | | |

| Female | 6.00 | 4 | NC* | Female | 44.18 | 28 | 63 #-> |
|--------|-------|----|-----|--------|-------|----|--------|
| Total | 13.85 | 12 | 87 | Total | 94.74 | 90 | 95 |

Shellburne Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|--------|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 1.43 | 3 | NC* | Male | 1.07 | 3 | NC* |
| Female | 0.71 | 3 | NC* | Female | 0.94 | 2 | NC* |
| Total | 2.14 | 6 | 280 #+ | Total | 2.01 | 5 | 249 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 0.48 | 0 | NC* | Male | 0.30 | 0 | NC* |
| Female | 0.45 | 0 | NC* | Female | 0.34 | 1 | NC* |
| Total | 0.93 | 0 | NC* | Total | 0.64 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>nphoma</u> | | |
| Male | 0.07 | 0 | NC* | Male | 1.19 | 1 | NC* |
| Female | 10.86 | 8 | 74 | Female | 1.31 | 1 | NC* |
| Total | 10.93 | 8 | 73 | Total | 2.50 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 0.98 | 1 | NC* |
| Female | 0.54 | 0 | NC* | Female | 0.55 | 1 | NC* |
| | | | | Total | 1.53 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 3.63 | 2 | NC* | | | | |
| Female | 4.69 | 7 | 149 | Female | 1.24 | 0 | NC* |
| Total | 8.32 | 9 | 108 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.56 | 0 | NC* | Male | 0.66 | 1 | NC* |
| Female | 0.22 | 0 | NC* | Female | 0.91 | 0 | NC* |
| Total | 0.78 | 0 | NC* | Total | 1.56 | 1 | NC* |
| Hodgkin's Disease (I | Hodgkin Lympho | oma) | | Prostate | | | |
| Male | 0.21 | 0 | NC* | Male | 9.87 | 8 | 81 |
| Female | 0.19 | 0 | NC* | | | | |
| Total | 0.39 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | Stomach | | | |
| Male | 0.92 | 0 | NC* | Male | 0.63 | 0 | NC* |
| Female | 0.66 | 1 | NC* | Female | 0.53 | 1 | NC* |
| Total | 1.58 | 1 | NC* | Total | 1.15 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.51 | 1 | NC* | Male | 0.30 | 0 | NC* |
| Female | 0.14 | 0 | NC* | | | | |
| Total | 0.66 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.72 | 1 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.73 | 0 | NC* | Female | 0.62 | 0 | NC* |
| Total | 1.46 | 1 | NC* | Total | 0.83 | 0 | NC* |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and Ut | terus, NOS | | |

| Male | 0.40 | 0 | NC* | | | | |
|-------------------|------|----|-----|-------------------|-------|----|-------|
| Female | 0.20 | 0 | NC* | Female | 2.06 | 3 | NC* |
| Total | 0.60 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 4.77 | 3 | NC* | Male | 30.88 | 26 | 84 > |
| Female | 4.69 | 7 | 149 | Female | 35.30 | 39 | 110 > |
| Total | 9.46 | 10 | 106 | Total | 66.18 | 65 | 98 |

Sherborn
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|----------------|------------|-----|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 2.96 | 2 | NC* | Male | 2.26 | 4 | NC* |
| Female | 0.92 | 1 | NC* | Female | 1.60 | 4 | NC* |
| Total | 3.88 | 3 | NC* | Total | 3.86 | 8 | 207 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 1.00 | 1 | NC* | Male | 0.64 | 2 | NC* |
| Female | 0.75 | 2 | NC* | Female | 0.50 | 0 | NC* |
| Total | 1.75 | 3 | NC* | Total | 1.13 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma_ | | |
| Male | 0.15 | 0 | NC* | Male | 2.47 | 1 | NC* |
| Female | 19.13 | 19 | 99 | Female | 1.93 | 0 | NC* |
| Total | 19.29 | 19 | 99 | Total | 4.41 | 1 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>ınx</u> | | |
| | | | | Male | 2.11 | 1 | NC* |
| Female | 0.98 | 0 | NC* | Female | 0.89 | 0 | NC* |
| | | | | Total | 3.00 | 1 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 7.52 | 9 | 120 | | | | |
| Female | 5.96 | 3 | NC* | Female | 2.15 | 2 | NC* |
| Total | 13.49 | 12 | 89 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.19 | 1 | NC* | Male | 1.38 | 2 | NC* |
| Female | 0.29 | 0 | NC* | Female | 1.16 | 1 | NC* |
| Total | 1.48 | 1 | NC* | Total | 2.54 | 3 | NC* |
| Hodgkin's Disease (| Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.40 | 0 | NC* | Male | 20.95 | 21 | 100 |
| Female | 0.32 | 0 | NC* | | | | |
| Total | 0.72 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | Stomach | | | |
| Male | 1.96 | 2 | NC* | Male | 1.31 | 2 | NC* |
| Female | 1.06 | 0 | NC* | Female | 0.64 | 1 | NC* |
| Total | 3.03 | 2 | NC* | Total | 1.94 | 3 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.11 | 1 | NC* | Male | 0.54 | 1 | NC* |
| Female | 0.26 | 0 | NC* | | | | |
| Total | 1.36 | 1 | NC* | | | | |

| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
|----------------------|---------------|----|-----|---------------------|---------------------|-----|------|
| Male | 1.50 | 4 | NC* | Male | 0.43 | 2 | NC* |
| Female | 1.07 | 1 | NC* | Female | 1.16 | 2 | NC* |
| Total | 2.57 | 5 | 194 | Total | 1.60 | 4 | NC* |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and L | <u> Iterus, NOS</u> | | |
| Male | 0.85 | 0 | NC* | | | | |
| Female | 0.26 | 1 | NC* | Female | 3.74 | 3 | NC* |
| Total | 1.12 | 1 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 10.00 | 2 | NC* | Male | 64.73 | 60 | 93 > |
| Female | 7.44 | 8 | 108 | Female | 55.91 | 49 | 88 > |
| Total | 17.44 | 10 | 57 | Total | 120.64 | 109 | 90 > |

Shirley
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|----------------|------------|-----|----------------------|---------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 3.74 | 8 | 214 | Male | 3.32 | 3 | NC* |
| Female | 1.17 | 1 | NC* | Female | 2.28 | 1 | NC* |
| Total | 4.91 | 9 | 183 | Total | 5.60 | 4 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 1.57 | 1 | NC* | Male | 0.82 | 0 | NC* |
| Female | 1.08 | 2 | NC* | Female | 0.62 | 1 | NC* |
| Total | 2.65 | 3 | NC* | Total | 1.44 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | <u>nphoma</u> | | |
| Male | 0.21 | 0 | NC* | Male | 3.64 | 1 | NC* |
| Female | 24.26 | 21 | 87 | Female | 2.60 | 8 | 308 #+ |
| Total | 24.46 | 21 | 86 | Total | 6.23 | 9 | 144 |
| Cervix Uteri | | | | Oral Cavity & Pharys | <u>1X</u> | | |
| | | | | Male | 2.93 | 1 | NC* |
| Female | 1.51 | 0 | NC* | Female | 1.13 | 1 | NC* |
| | | | | Total | 4.05 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 9.70 | 13 | 134 | | | | |
| Female | 7.54 | 7 | 93 | Female | 2.85 | 4 | NC* |
| Total | 17.24 | 20 | 116 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.56 | 2 | NC* | Male | 1.79 | 1 | NC* |
| Female | 0.36 | 0 | NC* | Female | 1.48 | 0 | NC* |
| Total | 1.92 | 2 | NC* | Total | 3.26 | 1 | NC* |
| Hodgkin's Disease (F | lodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.85 | 0 | NC* | Male | 26.80 | 26 | 97 |
| Female | 0.59 | 1 | NC* | | | | |
| Total | 1.44 | 1 | NC* | | | | |
| Kidney & Renal Pelvi | <u>s</u> | | | <u>Stomach</u> | | | |
| Male | 2.68 | 3 | NC* | Male | 1.70 | 3 | NC* |

| Female | 1.37 | 1 | NC* | Female | 0.82 | 1 | NC* |
|----------------------|----------------|----|-----|---------------------|-------------|-----|------|
| Total | 4.04 | 4 | NC* | Total | 2.51 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.47 | 2 | NC* | Male | 1.48 | 1 | NC* |
| Female | 0.32 | 1 | NC* | | | | |
| Total | 1.78 | 3 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.15 | 1 | NC* | Male | 0.77 | 2 | NC* |
| Female | 1.45 | 1 | NC* | Female | 1.92 | 2 | NC* |
| Total | 3.59 | 2 | NC* | Total | 2.69 | 4 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and L | Iterus, NOS | | |
| Male | 1.16 | 2 | NC* | | | | |
| Female | 0.34 | 0 | NC* | Female | 4.55 | 9 | 198 |
| Total | 1.49 | 2 | NC* | | | | |
| Lung and Bronchus | į | | | All Sites / Types | | | |
| Male | 12.88 | 13 | 101 | Male | 86.80 | 86 | 99 > |
| Female | 9.33 | 14 | 150 | Female | 72.31 | 85 | 118 |
| Total | 22.21 | 27 | 122 | Total | 159.12 | 171 | 107 |

Shrewsbury
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Ехр</u> | <u>Obs</u> | SIR |
|---------------------|----------------|------------|------------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 18.15 | 17 | 94 | Male | 13.57 | 16 | 118 |
| Female | 6.68 | 8 | 120 | Female | 10.38 | 12 | 116 |
| Total | 24.83 | 25 | 101 | Total | 23.95 | 28 | 117 |
| Brain and Other Ner | rvous System | | | Multiple Myeloma | | | |
| Male | 6.22 | 7 | 112 | Male | 3.81 | 2 | NC* |
| Female | 5.03 | 5 | 99 | Female | 3.38 | 6 | 177 |
| Total | 11.26 | 12 | 107 | Total | 7.20 | 8 | 111 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyi | mphoma | | |
| Male | 0.93 | 1 | NC* | Male | 15.25 | 21 | 138 |
| Female | 118.16 | 117 | 99 | Female | 13.50 | 11 | 81 |
| Total | 119.09 | 118 | 99 | Total | 28.75 | 32 | 111 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 12.09 | 9 | 74 |
| Female | 6.33 | 2 | NC* | Female | 5.76 | 3 | NC* |
| | | | | Total | 17.84 | 12 | 67 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 46.00 | 37 | 80 | | | | |
| Female | 43.56 | 47 | 108 | Female | 13.64 | 12 | 88 |
| Total | 89.56 | 84 | 94 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 6.97 | 2 | NC* | Male | 8.26 | 10 | 121 |
| Female | 2.07 | 2 | NC* | Female | 8.52 | 12 | 141 |
| Total | 9.04 | 4 | NC* | Total | 16.77 | 22 | 131 |
| Hodgkin's Disease | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |

| Male | 2.81 | 3 | NC* | Male | 123.13 | 118 | 96 |
|---------------------|----------------|----|--------|---------------------|---------------------|-----|-----|
| Female | 2.32 | 6 | 259 | | | | |
| Total | 5.13 | 9 | 175 | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | <u>Stomach</u> | | | |
| Male | 11.56 | 19 | 164 | Male | 7.92 | 8 | 101 |
| Female | 6.99 | 10 | 143 | Female | 4.66 | 3 | NC* |
| Total | 18.55 | 29 | 156 #+ | Total | 12.58 | 11 | 87 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 6.36 | 4 | NC* | Male | 4.36 | 5 | 115 |
| Female | 1.61 | 1 | NC* | | | | |
| Total | 7.97 | 5 | 63 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 9.33 | 10 | 107 | Male | 2.72 | 4 | NC* |
| Female | 7.31 | 4 | NC* | Female | 7.62 | 10 | 131 |
| Total | 16.64 | 14 | 84 | Total | 10.35 | 14 | 135 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and L | <u> Iterus, NOS</u> | | |
| Male | 4.99 | 3 | NC* | | | | |
| Female | 1.89 | 1 | NC* | Female | 22.62 | 24 | 106 |
| Total | 6.88 | 4 | NC* | | | | |
| Lung and Bronchus | <u>s</u> | | | All Sites / Types | | | |
| Male | 60.22 | 48 | 80 | Male | 389.68 | 360 | 92 |
| Female | 49.84 | 46 | 92 | Female | 367.79 | 373 | 101 |
| Total | 110.06 | 94 | 85 | Total | 757.47 | 733 | 97 |

Shutesbury Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|------------|------------|------------|----------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 1.02 | 0 | NC* | Male | 0.88 | 2 | NC* |
| Female | 0.32 | 0 | NC* | Female | 0.67 | 0 | NC* |
| Total | 1.34 | 0 | NC* | Total | 1.55 | 2 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.41 | 0 | NC* | Male | 0.23 | 0 | NC* |
| Female | 0.30 | 1 | NC* | Female | 0.17 | 0 | NC* |
| Total | 0.71 | 1 | NC* | Total | 0.40 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.06 | 0 | NC* | Male | 0.95 | 1 | NC* |
| Female | 7.37 | 8 | 108 | Female | 0.72 | 0 | NC* |
| Total | 7.43 | 8 | 108 | Total | 1.67 | 1 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>1X</u> | | |
| | | | | Male | 0.82 | 0 | NC* |
| Female | 0.45 | 0 | NC* | Female | 0.33 | 0 | NC* |
| | | | | Total | 1.15 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 2.64 | 3 | NC* | | | | |
| Female | 2.06 | 1 | NC* | Female | 0.85 | 0 | NC* |
| Total | 4.69 | 4 | NC* | | | | |

| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
|--------------------------|----------------|-----|-----|---------------------|------------|----|--------|
| Male | 0.43 | 0 | NC* | Male | 0.49 | 0 | NC* |
| Female | 0.10 | 0 | NC* | Female | 0.40 | 0 | NC* |
| Total | 0.53 | 0 | NC* | Total | 0.89 | 0 | NC* |
| Hodgkin's Disease (He | odgkin Lymphon | na) | | <u>Prostate</u> | | | |
| Male | 0.19 | 0 | NC* | Male | 7.42 | 7 | 94 |
| Female | 0.16 | 0 | NC* | | | | |
| Total | 0.34 | 0 | NC* | | | | |
| Kidney & Renal Pelvis | <u>i</u> | | | <u>Stomach</u> | | | |
| Male | 0.74 | 0 | NC* | Male | 0.47 | 2 | NC* |
| Female | 0.39 | 0 | NC* | Female | 0.22 | 0 | NC* |
| Total | 1.13 | 0 | NC* | Total | 0.69 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.41 | 0 | NC* | Male | 0.27 | 0 | NC* |
| Female | 0.09 | 0 | NC* | | | | |
| Total | 0.50 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.57 | 0 | NC* | Male | 0.19 | 0 | NC* |
| Female | 0.41 | 0 | NC* | Female | 0.56 | 0 | NC* |
| Total | 0.98 | 0 | NC* | Total | 0.75 | 0 | NC* |
| Liver and Intrahepatic | Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 0.32 | 0 | NC* | | | | |
| Female | 0.09 | 0 | NC* | Female | 1.39 | 1 | NC* |
| Total | 0.41 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 3.51 | 2 | NC* | Male | 23.50 | 17 | 72 > |
| Female | 2.62 | 1 | NC* | Female | 21.03 | 13 | 62 > |
| Total | 6.13 | 3 | NC* | Total | 44.52 | 30 | 67 #-> |

Somerset
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|-----|----------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 15.33 | 17 | 111 | Male | 10.24 | 5 | 49 |
| Female | 5.94 | 4 | NC* | Female | 7.79 | 7 | 90 |
| Total | 21.27 | 21 | 99 | Total | 18.03 | 12 | 67 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 4.43 | 7 | 158 | Male | 3.11 | 2 | NC* |
| Female | 3.77 | 5 | 132 | Female | 2.91 | 3 | NC* |
| Total | 8.20 | 12 | 146 | Total | 6.02 | 5 | 83 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.75 | 0 | NC* | Male | 11.71 | 16 | 137 |
| Female | 93.06 | 95 | 102 | Female | 11.19 | 17 | 152 |
| Total | 93.80 | 95 | 101 | Total | 22.90 | 33 | 144 |
| Cervix Uteri | | | | Oral Cavity & Pharys | <u>nx</u> | | |
| | | | | Male | 9.14 | 4 | NC* |
| Female | 4.41 | 4 | NC* | Female | 4.71 | 3 | NC* |

| | | | | Total | 13.85 | 7 | 51 |
|---------------------|-----------------|------------|-------|---------------------|--------------------|-----|--------|
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 38.32 | 27 | 70 | | | | |
| Female | 38.87 | 33 | 85 | Female | 10.63 | 9 | 85 |
| Total | 77.19 | 60 | 78 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 5.56 | 8 | 144 | Male | 6.77 | 14 | 207 #+ |
| Female | 1.84 | 2 | NC* | Female | 7.62 | 7 | 92 |
| Total | 7.40 | 10 | 135 | Total | 14.38 | 21 | 146 |
| Hodgkin's Disease | (Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 1.75 | 2 | NC* | Male | 99.26 | 128 | 129 ~+ |
| Female | 1.50 | 3 | NC* | | | | |
| Total | 3.24 | 5 | 154 | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | <u>Stomach</u> | | | |
| Male | 8.96 | 9 | 100 | Male | 6.58 | 10 | 152 |
| Female | 5.71 | 8 | 140 | Female | 4.19 | 3 | NC* |
| Total | 14.67 | 17 | 116 | Total | 10.76 | 13 | 121 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 4.94 | 4 | NC* | Male | 2.49 | 3 | NC* |
| Female | 1.31 | 0 | NC* | | | | |
| Total | 6.25 | 4 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 7.14 | 9 | 126 | Male | 1.84 | 0 | NC* |
| Female | 5.89 | 6 | 102 | Female | 5.00 | 6 | 120 |
| Total | 13.04 | 15 | 115 | Total | 6.84 | 6 | 88 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and L | <u>Jterus, NOS</u> | | |
| Male | 3.86 | 1 | NC* | | | | |
| Female | 1.65 | 0 | NC* | Female | 18.04 | 18 | 100 |
| Total | 5.51 | 1 | NC* | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 49.17 | 53 | 108 | Male | 311.33 | 340 | 109 |
| Female | 42.02 | 28 | 67 #- | Female | 300.24 | 280 | 93 |
| Total | 91.18 | 81 | 89 | Total | 611.57 | 620 | 101 |

Somerville
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|------------|---------------------|---------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 37.61 | 34 | 90 | Male | 29.66 | 15 | 51 ~- |
| Female | 17.43 | 17 | 98 | Female | 27.78 | 16 | 58 #- |
| Total | 55.04 | 51 | 93 | Total | 57.44 | 31 | 54 ^- |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 13.90 | 12 | 86 | Male | 7.69 | 8 | 104 |
| Female | 12.97 | 12 | 92 | Female | 8.42 | 6 | 71 |
| Total | 26.87 | 24 | 89 | Total | 16.11 | 14 | 87 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | <u>nphoma</u> | | |
| Male | 1.90 | 0 | NC* | Male | 34.00 | 22 | 65 #- |

| Female | 286.01 | 240 | 84 ~- | Female | 34.86 | 29 | 83 |
|-------------------|-------------------|-------|--------|--------------------|--------------------|------------|--------|
| Total | 287.91 | 240 | 83 ~- | Total | 68.86 | 51 | 74 #- |
| Cervix Uteri | | | | Oral Cavity & Phar | <u>ynx</u> | | |
| | | | | Male | 24.38 | 34 | 139 |
| Female | 17.85 | 16 | 90 | Female | 14.17 | 15 | 106 |
| | | | | Total | 38.54 | 49 | 127 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 95.13 | 120 | 126 #+ | | | | |
| Female | 114.70 | 141 | 123 #+ | Female | 34.07 | 23 | 68 |
| Total | 209.83 | 261 | 124 ^+ | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 13.69 | 20 | 146 | Male | 16.86 | 14 | 83 |
| Female | 5.37 | 4 | NC* | Female | 22.18 | 17 | 77 |
| Total | 19.06 | 24 | 126 | Total | 39.03 | 31 | 79 |
| Hodgkin's Diseas | se (Hodgkin Lymph | noma) | | <u>Prostate</u> | | | |
| Male | 8.00 | 9 | 113 | Male | 233.82 | 212 | 91 |
| Female | 7.18 | 6 | 84 | | | | |
| Total | 15.17 | 15 | 99 | | | | |
| Kidney & Renal F | <u></u> | | | <u>Stomach</u> | | | |
| Male | 23.47 | 23 | 98 | Male | 16.69 | 16 | 96 |
| Female | 17.01 | 15 | 88 | Female | 12.70 | 21 | 165 #+ |
| Total | 40.49 | 38 | 94 | Total | 29.39 | 37 | 126 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 12.26 | 10 | 82 | Male | 14.90 | 20 | 134 |
| Female | 3.62 | 4 | NC* | | | | |
| Total | 15.88 | 14 | 88 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | _ | |
| Male | 20.21 | 15 | 74 | Male | 6.76 | 5 | 74 |
| Female | 18.80 | 26 | 138 | Female | 22.47 | 24 | 107 |
| Total | 39.01 | 41 | 105 | Total | 29.23 | 29 | 99 |
| Liver and Intrahe | - | 40 | 400 | Uteri, Corpus and | <u>Uterus, NOS</u> | | |
| Male | 10.01 | 10 | 100 | | 54.05 | 07 | 74 !! |
| Female | 4.89 | 8 | 164 | Female | 51.95 | 37 | 71 #- |
| Total | 14.90 | 18 | 121 | All 0:4 / T | | | |
| Lung and Bronch | | 4.45 | 400 # | All Sites / Types | 705 50 | 700 | 400 |
| Male | 119.08 | 145 | 122 #+ | Male | 795.50 | 799 970 | 100 |
| Female | 118.92 | 125 | 105 | Female | 921.73 | 870 | 94 |
| Total | 237.99 | 270 | 113 #+ | Total | 1717.23 | 1669 | 97 |

South Hadley
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|----------------------|------------|------------|------------|------------------|------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 12.28 | 19 | 155 | Male | 8.32 | 15 | 180 #+ |
| Female | 5.08 | 7 | 138 | Female | 7.27 | 10 | 138 |
| Total | 17.36 | 26 | 150 | Total | 15.59 | 25 | 160 #+ |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |

| Bladder, Urinary | Ехр | <u>Obs</u> | <u>SIR</u> | Melanoma of Skin | <u>Exp</u> | <u>Obs</u> | SII |
|-------------------------------|---------------|------------------|-------------------|-----------------------------|--------------------|------------|-----|
| | Expe | ected and Observ | ed Case Counts, w | ith Standardized Incidence | Ratios, 1996 – 200 | 0 | |
| i otai | . 1.00 | O r | | hampton | V11.21 | 101 | J |
| Total | 74.55 | 64 | 86 | Total | 511.27 | 481 | g |
| Female | 35.30 | 33 | 93 | Female | 261.52 | 250 | 9 |
| Male | 39.25 | 31 | 79 | Male | 249.75 | 231 | g |
| Lung and Bronchus | | U | INO | All Sites / Types | | | |
| Total | 4.52 | 0 | NC* | remale | 13.10 | 11 | |
| Female | 1.42 | 0 | NC* | Female | 15.16 | 11 | - |
| Liver and intranepat Male | 3.10 | 0 | NC* | oten, corpus and t | Jielus, NOS | | |
| lotal Liver and Intrahepat | | I | UZ | Uteri, Corpus and U | | 1 | 11 |
| Female Total | 5.39 11.24 | 4 7 | NC" 62 | Female Total | 5.28 6.82 | 4 7 | N: |
| Female | 5.89 | 3 4 | NC* | Female | 5.28 | 3 4 | N: |
| <u>Leukemia</u> Male | 5.85 | 3 | NC* | <u>rnyroid</u> Male | 1.54 | 3 | N |
| Leukemia | J.UZ | J | INO | <u>Thyroid</u> | | | |
| Total | 5.02 | 3 | NC* | | | | |
| Female | 1.08 | 0 | NC* | iviaic | ۷.01 | J | 20 |
| Male | 3.93 | 3 | NC* | <u>restis</u> Male | 2.31 | 6 | 25 |
| Larynx | 14.14 | 10 | 03 | Testis | 0.90 | U | , |
| Total | 12.12 | 10 | 83 | Total | 8.90 | 8 | 111 |
| Female | 4.92 | 1 | NC* | Female | 3.63 | 4 | N(|
| Male | 7.20 | 9 | 125 | <u>Stomach</u> Male | 5.27 | 4 | N |
| Kidney & Renal Pelv | | J | INO | Stomach_ | | | |
| Total | 3.24 | 3 | NC* | | | | |
| Female | 1.70 | 2 | NC* | Maio | 70.10 | 00 | 07 |
| Male | 1.54 | <u>smu,</u> 1 | NC* | Male | 78.73 | 53 | 67 |
| Hodgkin's Disease (| | | | <u>Prostate</u> | | | · |
| Total | 6.00 | 8 | 133 | Total | 11.90 | 17 | 1 |
| Female | 1.57 | 1 | NC* | Female | 6.49 | 7 | 1 |
| Male | 4.43 | 7 | 158 | Male | 5.41 | 10 | 1 |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Total | 64.04 | 49 | 77 | - 2 | | | •• |
| Female | 33.35 | 29 | 87 | Female | 9.42 | 12 | 12 |
| Male | 30.70 | 20 | 65 | <u> w. J</u> | | | |
| Colon / Rectum | | | | <u>Ovary</u> | 11.00 | 1.1 | ` |
| i emale | 4.50 | J | 114 | Total | 11.38 | 11 | (|
| Female | 4.38 | 5 | 114 | Female | 4.06 | 3 | N(|
| OCIVIX OLCII | | | | Male | 7.32 | 8 | 10 |
| Cervix Uteri | 01.10 | O1 | 107 | Oral Cavity & Phar | | 27 | 12 |
| Total | 81.18 | 87 | 107 | Total | 19.43 | 24 | 12 |
| Female | 80.58 | 86 | 107 | Female | 9.88 | 12 | 12 |
| <u>Breast</u> Male | 0.60 | 1 | NC* | Male | 9.55 | 12 | 12 |
| Total | 7.26 | 8 | 110 | Total Non-Hodgkin('s) Ly | 4.96 | 5 | 10 |
| Female | 3.59 | 2 | NC* | Female | 2.47 | 0 | NO |
| Male | 3.67 | 6 | 164 Not | Male | 2.49 | 5 | 20 |
| | | • | 404 | | 2.42 | _ | |

| Male | 3.26 | 2 | NC* | Male | 2.49 | 2 | NC* |
|-----------------------|-------------|----|-----|-----------------------|------------|-----|-----|
| Female | 1.13 | 0 | NC* | Female | 1.85 | 2 | NC* |
| Total | 4.39 | 2 | NC* | Total | 4.35 | 4 | NC* |
| Brain and Other Ner | | _ | 140 | Multiple Myeloma | 4.00 | 7 | 110 |
| Male | 1.13 | 3 | NC* | Male | 0.70 | 0 | NC* |
| Female | 0.89 | 0 | NC* | Female | 0.59 | 0 | NC* |
| Total | 2.02 | 3 | NC* | Total | 1.28 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | | | |
| Male | 0.17 | 0 | NC* | Male | 2.76 | 1 | NC* |
| Female | 21.50 | 15 | 70 | Female | 2.33 | 1 | NC* |
| Total | 21.66 | 15 | 69 | Total | 5.09 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>/nx</u> | | |
| | | | | Male | 2.28 | 0 | NC* |
| Female | 1.14 | 2 | NC* | Female | 1.02 | 1 | NC* |
| | | | | Total | 3.30 | 1 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 8.28 | 9 | 109 | | | | |
| Female | 7.33 | 7 | 96 | Female | 2.46 | 3 | NC* |
| Total | 15.60 | 16 | 103 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.28 | 1 | NC* | Male | 1.51 | 0 | NC* |
| Female | 0.35 | 0 | NC* | Female | 1.43 | 1 | NC* |
| Total | 1.63 | 1 | NC* | Total | 2.93 | 1 | NC* |
| Hodgkin's Disease (| | | | <u>Prostate</u> | | | |
| Male | 0.48 | 2 | NC* | Male | 22.43 | 19 | 85 |
| Female | 0.40 | 0 | NC* | | | | |
| Total | 0.88 | 2 | NC* | | | | |
| Kidney & Renal Pelv | | • | NOt | <u>Stomach</u> | 4.44 | 4 | NOt |
| Male | 2.14 | 0 | NC* | Male | 1.44 | 1 | NC* |
| Female | 1.24 | 2 | NC* | Female | 0.78 | 1 | NC* |
| Total | 3.37 | 2 | NC* | Total | 2.22 | 2 | NC* |
| <u>Larynx</u> Male | 1.18 | 0 | NC* | <u>Testis</u> Male | 0.70 | 2 | NC* |
| Female | 0.29 | 1 | NC* | Male | 0.70 | 2 | INC |
| Total | 1.47 | 1 | NC* | | | | |
| <u>Leukemia</u> | 1.47 | | NO | <u>Thyroid</u> | | | |
| Male | 1.69 | 2 | NC* | <u>myroid</u> Male | 0.49 | 0 | NC* |
| Female | 1.28 | 0 | NC* | Female | 1.37 | 3 | NC* |
| Total | 2.96 | 2 | NC* | Total | 1.86 | 3 | NC* |
| Liver and Intrahepat | | _ | | Uteri, Corpus and L | | · | |
| Male | 0.92 | 0 | NC* | <u>,,</u> | | | |
| Female | 0.32 | 0 | NC* | Female | 4.15 | 3 | NC* |
| Total | 1.24 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 10.85 | 8 | 74 | Male | 70.66 | 57 | 81 |
| Female | 8.74 | 10 | 114 | Female | 65.00 | 57 | 88 |
| Total | 19.59 | 18 | 92 | Total | 135.66 | 114 | 84 |
| | | | | | | | |

Southborough
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|-------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.26 | 2 | NC* | Male | 3.51 | 5 | 143 |
| Female | 1.50 | 0 | NC* | Female | 2.68 | 3 | NC* |
| Total | 5.76 | 2 | NC* | Total | 6.19 | 8 | 129 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 1.64 | 3 | NC* | Male | 0.93 | 0 | NC* |
| Female | 1.27 | 0 | NC* | Female | 0.80 | 1 | NC* |
| Total | 2.91 | 3 | NC* | Total | 1.73 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.23 | 0 | NC* | Male | 3.84 | 4 | NC* |
| Female | 30.75 | 42 | 137 | Female | 3.20 | 6 | 188 |
| Total | 30.98 | 42 | 136 | Total | 7.04 | 10 | 142 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 3.22 | 2 | NC* |
| Female | 1.68 | 1 | NC* | Female | 1.43 | 0 | NC* |
| | | | | Total | 4.65 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.93 | 2 | NC* | | | | |
| Female | 9.79 | 8 | 82 | Female | 3.50 | 2 | NC* |
| Total | 20.72 | 10 | 48 #- | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.75 | 2 | NC* | Male | 2.02 | 3 | NC* |
| Female | 0.47 | 1 | NC* | Female | 1.90 | 0 | NC* |
| Total | 2.22 | 3 | NC* | Total | 3.91 | 3 | NC* |
| Hodgkin's Disease (I | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.76 | 3 | NC* | Male | 30.44 | 23 | 76 |
| Female | 0.59 | 0 | NC* | | | | |
| Total | 1.35 | 3 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |
| Male | 2.95 | 3 | NC* | Male | 1.92 | 1 | NC* |
| Female | 1.71 | 3 | NC* | Female | 1.04 | 1 | NC* |
| Total | 4.67 | 6 | 129 | Total | 2.96 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.64 | 0 | NC* | Male | 1.15 | 2 | NC* |
| Female | 0.41 | 0 | NC* | | | | |
| Total | 2.05 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.35 | 2 | NC* | Male | 0.74 | 0 | NC* |
| Female | 1.79 | 1 | NC* | Female | 2.05 | 2 | NC* |
| Total | 4.13 | 3 | NC* | Total | 2.79 | 2 | NC* |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 1.28 | 3 | NC* | | | | |
| Female | 0.43 | 1 | NC* | Female | 5.91 | 4 | NC* |

| Total | 1.71 | 4 | NC* | | | | |
|--------------------------|-------|----|-------|-------------------|--------|-----|----|
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 14.49 | 7 | 48 #- | Male | 96.13 | 78 | 81 |
| Female | 11.90 | 9 | 76 | Female | 90.88 | 90 | 99 |
| Total | 26.39 | 16 | 61 #- | Total | 187.01 | 168 | 90 |

SouthbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|--------|---------------------|------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 11.86 | 18 | 152 | Male | 7.85 | 4 | NC* |
| Female | 5.49 | 2 | NC* | Female | 6.85 | 2 | NC* |
| Total | 17.35 | 20 | 115 | Total | 14.70 | 6 | 41 #- |
| Brain and Other Nerv | vous System | | | Multiple Myeloma | | | |
| Male | 3.57 | 9 | 252 #+ | Male | 2.33 | 4 | NC* |
| Female | 3.41 | 4 | NC* | Female | 2.56 | 1 | NC* |
| Total | 6.98 | 13 | 186 | Total | 4.88 | 5 | 102 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyı | mphoma | | |
| Male | 0.55 | 1 | NC* | Male | 9.24 | 7 | 76 |
| Female | 76.66 | 73 | 95 | Female | 9.95 | 9 | 90 |
| Total | 77.21 | 74 | 96 | Total | 19.19 | 16 | 83 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 6.66 | 5 | 75 |
| Female | 3.91 | 4 | NC* | Female | 4.03 | 6 | 149 |
| | | | | Total | 10.69 | 11 | 103 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 29.32 | 29 | 99 | | | | |
| Female | 36.34 | 30 | 83 | Female | 8.94 | 11 | 123 |
| Total | 65.67 | 59 | 90 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 4.02 | 0 | NC* | Male | 5.12 | 8 | 156 |
| Female | 1.70 | 1 | NC* | Female | 7.02 | 7 | 100 |
| Total | 5.72 | 1 | NC* | Total | 12.14 | 15 | 124 |
| Hodgkin's Disease (H | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 1.62 | 2 | NC* | Male | 69.65 | 67 | 96 |
| Female | 1.50 | 2 | NC* | | | | |
| Total | 3.13 | 4 | NC* | | | | |
| Kidney & Renal Pelv | | | | <u>Stomach</u> | | | |
| Male | 6.65 | 7 | 105 | Male | 5.14 | 3 | NC* |
| Female | 4.80 | 1 | NC* | Female | 4.06 | 3 | NC* |
| Total | 11.45 | 8 | 70 | Total | 9.20 | 6 | 65 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 3.48 | 9 | 258 #+ | Male | 2.58 | 3 | NC* |
| Female | 1.01 | 1 | NC* | | | | |
| Total | 4.49 | 10 | 223 #+ | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 5.80 | 4 | NC* | Male | 1.48 | 0 | NC* |
| Female | 5.55 | 6 | 108 | Female | 4.56 | 3 | NC* |

| Total | 11.35 | 10 | 88 | Total | 6.04 | 3 | NC* | | |
|----------------------|----------------|----|-------|-------------------------------|--------|-----|-------|--|--|
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | | |
| Male | 2.83 | 2 | NC* | | | | | | |
| Female | 1.52 | 1 | NC* | Female | 14.30 | 6 | 42 #- | | |
| Total | 4.34 | 3 | NC* | | | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | | | |
| Male | 35.83 | 40 | 112 | Male | 231.67 | 243 | 105 | | |
| Female | 34.68 | 17 | 49 ~- | Female | 259.71 | 209 | 80 ~- | | |
| Total | 70.52 | 57 | 81 | Total | 491.38 | 452 | 92 | | |

Southwick
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|-------------|------------|------------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.69 | 4 | NC* | Male | 3.84 | 5 | 130 |
| Female | 1.55 | 3 | NC* | Female | 2.84 | 6 | 211 |
| Total | 6.24 | 7 | 112 | Total | 6.68 | 11 | 165 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 1.80 | 2 | NC* | Male | 1.01 | 0 | NC* |
| Female | 1.35 | 1 | NC* | Female | 0.82 | 1 | NC* |
| Total | 3.14 | 3 | NC* | Total | 1.83 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyi | mphoma | | |
| Male | 0.25 | 0 | NC* | Male | 4.23 | 2 | NC* |
| Female | 31.89 | 30 | 94 | Female | 3.34 | 5 | 150 |
| Total | 32.14 | 30 | 93 | Total | 7.57 | 7 | 92 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 3.48 | 1 | NC* |
| Female | 1.82 | 1 | NC* | Female | 1.48 | 0 | NC* |
| | | | | Total | 4.96 | 1 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 11.99 | 9 | 75 | | | | |
| Female | 10.00 | 7 | 70 | Female | 3.67 | 4 | NC* |
| Total | 21.99 | 16 | 73 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.89 | 2 | NC* | Male | 2.20 | 2 | NC* |
| Female | 0.48 | 0 | NC* | Female | 1.95 | 4 | NC* |
| Total | 2.37 | 2 | NC* | Total | 4.15 | 6 | 144 |
| Hodgkin's Disease (H | | | | <u>Prostate</u> | | | |
| Male | 0.85 | 1 | NC* | Male | 32.61 | 26 | 80 |
| Female | 0.66 | 0 | NC* | | | | |
| Total | 1.52 | 1 | NC* | | | | |
| Kidney & Renal Pelvi | | | | <u>Stomach</u> | | | |
| Male | 3.21 | 4 | NC* | Male | 2.12 | 2 | NC* |
| Female | 1.79 | 2 | NC* | Female | 1.07 | 2 | NC* |
| Total | 4.99 | 6 | 120 | Total | 3.19 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.76 | 2 | NC* | Male | 1.33 | 2 | NC* |

| Female | 0.42 | 0 | NC* | | | | |
|-----------------------|--------------|----|-----|---------------------|---------------------|-----|-----|
| Total | 2.18 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.58 | 2 | NC* | Male | 0.82 | 0 | NC* |
| Female | 1.87 | 0 | NC* | Female | 2.25 | 3 | NC* |
| Total | 4.45 | 2 | NC* | Total | 3.07 | 3 | NC* |
| Liver and Intrahepati | c Bile Ducts | | | Uteri, Corpus and L | <u> Iterus, NOS</u> | | |
| Male | 1.39 | 2 | NC* | | | | |
| Female | 0.44 | 1 | NC* | Female | 6.10 | 7 | 115 |
| Total | 1.83 | 3 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 15.68 | 24 | 153 | Male | 104.48 | 99 | 95 |
| Female | 12.34 | 11 | 89 | Female | 94.39 | 93 | 99 |
| Total | 28.02 | 35 | 125 | Total | 198.87 | 192 | 97 |

SpencerExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|------------|---------------------|------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 7.31 | 7 | 96 | Male | 5.40 | 1 | NC* |
| Female | 2.57 | 4 | NC* | Female | 4.16 | 3 | NC* |
| Total | 9.87 | 11 | 111 | Total | 9.56 | 4 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 2.49 | 1 | NC* | Male | 1.52 | 0 | NC* |
| Female | 2.01 | 1 | NC* | Female | 1.29 | 2 | NC* |
| Total | 4.50 | 2 | NC* | Total | 2.81 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyı | mphoma | | |
| Male | 0.37 | 0 | NC* | Male | 6.11 | 8 | 131 |
| Female | 45.83 | 40 | 87 | Female | 5.25 | 10 | 191 |
| Total | 46.20 | 40 | 87 | Total | 11.35 | 18 | 159 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 4.82 | 2 | NC* |
| Female | 2.60 | 7 | 270 #+ | Female | 2.22 | 3 | NC* |
| | | | | Total | 7.04 | 5 | 71 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 18.48 | 10 | 54 #- | | | | |
| Female | 16.79 | 18 | 107 | Female | 5.34 | 8 | 150 |
| Total | 35.28 | 28 | 79 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 2.78 | 3 | NC* | Male | 3.32 | 6 | 181 |
| Female | 0.79 | 0 | NC* | Female | 3.27 | 1 | NC* |
| Total | 3.57 | 3 | NC* | Total | 6.58 | 7 | 106 |
| Hodgkin's Disease (F | lodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 1.13 | 3 | NC* | Male | 48.84 | 28 | 57 ~- |
| Female | 0.99 | 3 | NC* | | | | |
| Total | 2.12 | 6 | 283 #+ | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |

| Male | 4.58 | 7 | 153 | Male | 3.21 | 0 | NC* |
|----------------------|---------------|----|-----|---------------------|-------------|-----|-------|
| Female | 2.69 | 3 | NC* | Female | 1.81 | 2 | NC* |
| Total | 7.26 | 10 | 138 | Total | 5.03 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 2.52 | 0 | NC* | Male | 1.76 | 1 | NC* |
| Female | 0.61 | 0 | NC* | | | | |
| Total | 3.12 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 3.74 | 2 | NC* | Male | 1.09 | 2 | NC* |
| Female | 2.89 | 6 | 208 | Female | 3.19 | 5 | 157 |
| Total | 6.63 | 8 | 121 | Total | 4.28 | 7 | 164 |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and L | Jterus, NOS | | |
| Male | 1.98 | 0 | NC* | | | | |
| Female | 0.73 | 1 | NC* | Female | 8.65 | 6 | 69 |
| Total | 2.71 | 1 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 23.87 | 22 | 92 | Male | 155.39 | 112 | 72 ^- |
| Female | 18.89 | 27 | 143 | Female | 142.68 | 157 | 110 |
| Total | 42.76 | 49 | 115 | Total | 298.07 | 269 | 90 |

Springfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------|--------------|------------|--------|---------------------|------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 80.46 | 73 | 91 | Male | 57.07 | 32 | 56 ^- |
| Female | 35.30 | 32 | 91 | Female | 52.05 | 30 | 58 ~- |
| Total | 115.76 | 105 | 91 | Total | 109.12 | 62 | 57 ^- |
| Brain and Other Ne | rvous System | | | Multiple Myeloma | | | |
| Male | 27.36 | 21 | 77 | Male | 16.21 | 21 | 130 |
| Female | 25.95 | 23 | 89 | Female | 17.10 | 11 | 64 |
| Total | 53.30 | 44 | 83 | Total | 33.31 | 32 | 96 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 3.92 | 5 | 127 | Male | 66.42 | 70 | 105 |
| Female | 563.96 | 503 | 89 ~- | Female | 69.14 | 58 | 84 |
| Total | 567.88 | 508 | 89 #- | Total | 135.56 | 128 | 94 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>/nx</u> | | |
| | | | | Male | 48.67 | 55 | 113 |
| Female | 31.82 | 32 | 101 | Female | 28.37 | 24 | 85 |
| | | | | Total | 77.04 | 79 | 103 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 201.29 | 209 | 104 | | | | |
| Female | 231.96 | 224 | 97 | Female | 66.41 | 56 | 84 |
| Total | 433.25 | 433 | 100 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 28.65 | 41 | 143 #+ | Male | 35.48 | 38 | 107 |
| Female | 10.90 | 16 | 147 | Female | 45.01 | 33 | 73 |
| Total | 39.55 | 57 | 144 #+ | Total | 80.49 | 71 | 88 |

| Hodgkin's Disease | (Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
|---------------------|-----------------|------|--------|-------------------|-------------|------|-------|
| Male | 13.12 | 11 | 84 | Male | 499.84 | 498 | 100 |
| Female | 12.77 | 6 | 47 | | | | |
| Total | 25.89 | 17 | 66 | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | Stomach . | | | |
| Male | 47.89 | 50 | 104 | Male | 34.98 | 33 | 94 |
| Female | 34.24 | 35 | 102 | Female | 25.50 | 29 | 114 |
| Total | 82.13 | 85 | 103 | Total | 60.49 | 62 | 103 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 25.35 | 33 | 130 | Male | 21.26 | 15 | 71 |
| Female | 7.42 | 4 | NC* | | | | |
| Total | 32.77 | 37 | 113 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 42.11 | 30 | 71 | Male | 11.51 | 5 | 43 |
| Female | 38.77 | 24 | 62 #- | Female | 39.02 | 35 | 90 |
| Total | 80.88 | 54 | 67 ~- | Total | 50.54 | 40 | 79 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and | Uterus, NOS | | |
| Male | 20.47 | 32 | 156 #+ | | | | |
| Female | 9.91 | 12 | 121 | Female | 105.03 | 113 | 108 |
| Total | 30.38 | 44 | 145 #+ | | | | |
| Lung and Bronchus | <u>3</u> | | | All Sites / Types | | | |
| Male | 252.80 | 280 | 111 | Male | 1647.54 | 1676 | 102 |
| Female | 242.03 | 209 | 86 #- | Female | 1830.24 | 1645 | 90 ^- |
| Total | 494.82 | 489 | 99 | Total | 3477.79 | 3321 | 95 ~- |

SterlingExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Exp | <u>Obs</u> | SIR | | Exp | <u>Obs</u> | SIR |
|----------------------|-------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.21 | 2 | NC* | Male | 3.46 | 2 | NC* |
| Female | 1.39 | 3 | NC* | Female | 2.49 | 2 | NC* |
| Total | 5.60 | 5 | 89 | Total | 5.95 | 4 | NC* |
| Brain and Other Nerv | vous System | | | Multiple Myeloma | | | |
| Male | 1.60 | 2 | NC* | Male | 0.93 | 2 | NC* |
| Female | 1.17 | 1 | NC* | Female | 0.74 | 1 | NC* |
| Total | 2.77 | 3 | NC* | Total | 1.66 | 3 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | <u>nphoma</u> | | |
| Male | 0.23 | 0 | NC* | Male | 3.78 | 5 | 132 |
| Female | 28.57 | 28 | 98 | Female | 2.94 | 3 | NC* |
| Total | 28.79 | 28 | 97 | Total | 6.72 | 8 | 119 |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>1X</u> | | |
| | | | | Male | 3.19 | 3 | NC* |
| Female | 1.56 | 1 | NC* | Female | 1.33 | 0 | NC* |
| | | | | Total | 4.52 | 3 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.77 | 10 | 93 | | | | |
| Female | 9.05 | 5 | 55 | Female | 3.25 | 2 | NC* |

| Total | 19.82 | 15 | 76 | | | | |
|----------------------|----------------|------------|-------|---------------------|-------------|-----|-----|
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.73 | 2 | NC* | Male | 1.99 | 2 | NC* |
| Female | 0.43 | 0 | NC* | Female | 1.75 | 2 | NC* |
| Total | 2.16 | 2 | NC* | Total | 3.74 | 4 | NC* |
| Hodgkin's Disease (| Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 0.72 | 0 | NC* | Male | 29.95 | 29 | 97 |
| Female | 0.54 | 3 | NC* | | | | |
| Total | 1.26 | 3 | NC* | | | | |
| Kidney & Renal Pelv | <u>/is</u> | | | <u>Stomach</u> | | | |
| Male | 2.94 | 3 | NC* | Male | 1.89 | 0 | NC* |
| Female | 1.58 | 0 | NC* | Female | 0.97 | 1 | NC* |
| Total | 4.52 | 3 | NC* | Total | 2.86 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.63 | 0 | NC* | Male | 1.06 | 4 | NC* |
| Female | 0.38 | 0 | NC* | | | | |
| Total | 2.00 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.31 | 3 | NC* | Male | 0.72 | 0 | NC* |
| Female | 1.66 | 2 | NC* | Female | 1.90 | 2 | NC* |
| Total | 3.97 | 5 | 126 | Total | 2.62 | 2 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and U | Iterus, NOS | | |
| Male | 1.27 | 2 | NC* | | | | |
| Female | 0.40 | 0 | NC* | Female | 5.49 | 5 | 91 |
| Total | 1.67 | 2 | NC* | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 14.32 | 6 | 42 #- | Male | 94.65 | 84 | 89 |
| Female | 10.93 | 13 | 119 | Female | 84.19 | 82 | 97 |
| Total | 25.25 | 19 | 75 | Total | 178.84 | 166 | 93 |

StockbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 1.97 | 2 | NC* | Male | 1.30 | 1 | NC* |
| Female | 0.77 | 1 | NC* | Female | 1.06 | 1 | NC* |
| Total | 2.74 | 3 | NC* | Total | 2.36 | 2 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.55 | 1 | NC* | Male | 0.40 | 0 | NC* |
| Female | 0.49 | 0 | NC* | Female | 0.38 | 1 | NC* |
| Total | 1.05 | 1 | NC* | Total | 0.78 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | <u>nphoma</u> | | |
| Male | 0.10 | 2 | NC* | Male | 1.50 | 2 | NC* |
| Female | 12.58 | 11 | 87 | Female | 1.45 | 0 | NC* |
| Total | 12.67 | 13 | 103 | Total | 2.94 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyn | <u>IX</u> | | |
| | | | | Male | 1.14 | 2 | NC* |

| Female | 0.61 | 0 | NC* | Female | 0.63 | 0 | NC* |
|----------------------|----------------|------------|-----|---------------------|------------|----|------|
| | | | | Total | 1.77 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 4.89 | 6 | 123 | | | | |
| Female | 5.03 | 6 | 119 | Female | 1.43 | 1 | NC* |
| Total | 9.92 | 12 | 121 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 0.70 | 2 | NC* | Male | 0.86 | 0 | NC* |
| Female | 0.24 | 1 | NC* | Female | 0.98 | 1 | NC* |
| Total | 0.93 | 3 | NC* | Total | 1.84 | 1 | NC* |
| Hodgkin's Disease (| Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 0.22 | 0 | NC* | Male | 12.26 | 9 | 73 |
| Female | 0.20 | 0 | NC* | | | | |
| Total | 0.42 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>vis</u> | | | <u>Stomach</u> | | | |
| Male | 1.15 | 0 | NC* | Male | 0.84 | 1 | NC* |
| Female | 0.75 | 0 | NC* | Female | 0.55 | 1 | NC* |
| Total | 1.89 | 0 | NC* | Total | 1.39 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.62 | 2 | NC* | Male | 0.31 | 0 | NC* |
| Female | 0.17 | 0 | NC* | | | | |
| Total | 0.79 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.92 | 0 | NC* | Male | 0.23 | 0 | NC* |
| Female | 0.77 | 0 | NC* | Female | 0.70 | 0 | NC* |
| Total | 1.69 | 0 | NC* | Total | 0.93 | 0 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 0.49 | 0 | NC* | | | | |
| Female | 0.21 | 0 | NC* | Female | 2.43 | 0 | NC* |
| Total | 0.70 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 6.21 | 5 | 80 | Male | 39.21 | 37 | 94 > |
| Female | 5.40 | 4 | NC* | Female | 39.71 | 28 | 71 > |
| Total | 11.61 | 9 | 78 | Total | 78.93 | 65 | 82 > |
| | | | | | | | |

StonehamExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|-----|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 16.08 | 10 | 62 | Male | 10.97 | 11 | 100 |
| Female | 6.89 | 7 | 102 | Female | 8.99 | 11 | 122 |
| Total | 22.97 | 17 | 74 | Total | 19.96 | 22 | 110 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 4.84 | 2 | NC* | Male | 3.24 | 3 | NC* |
| Female | 4.34 | 6 | 138 | Female | 3.29 | 1 | NC* |
| Total | 9.17 | 8 | 87 | Total | 6.52 | 4 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |

| Male | 0.78 | 0 | NC* | Male | 12.62 | 9 | 71 |
|---------------------|----------------|-------------|--------|---------------------|---------------------|-----|----------|
| | 102.86 | 137 | 133 ~+ | | 12.02 | 10 | 71 |
| Female Total | | 137 | 132 ~+ | Female Total | | 19 | 79 75 |
| | 103.63 | 137 | 132 ~+ | Oral Cavity & Phar | 25.35 | 19 | 75 |
| <u>Cervix Uteri</u> | | | | Male | 9.59 | 10 | 104 |
| Famala | F 40 | 7 | 405 | | | | |
| Female | 5.18 | 7 | 135 | Female | 5.28 | 6 | 114 |
| Oalan / Daatana | | | | Total | 14.87 | 16 | 108 |
| Colon / Rectum | 40.40 | 50 | 404 | <u>Ovary</u> | | | |
| Male | 40.18 | 50 | 124 | Famala | 44.00 | 40 | 405 |
| Female | 45.23 | 53 | 117 | Female | 11.90 | 16 | 135 |
| Total | 85.41 | 103 | 121 | | | | |
| Esophagus | F 70 | _ | 0.7 | <u>Pancreas</u> | 7.00 | 40 | 400 |
| Male | 5.76 | 5 | 87 | Male | 7.09 | 13 | 183 |
| Female | 2.13 | 1 | NC* | Female | 8.80 | 18 | 205 ~+ |
| Total | 7.89 | 6 | 76 | Total | 15.88 | 31 | 195 ~+ |
| Hodgkin's Disease | | | 200 # | <u>Prostate</u> | 101.01 | 400 | 407 |
| Male | 2.11 | 7 | 332 #+ | Male | 101.61 | 109 | 107 |
| Female | 1.88 | 1 | NC* | | | | |
| Total | 3.99 | 8 | 201 | | | | |
| Kidney & Renal Pel | | | | <u>Stomach</u> | | | |
| Male | 9.39 | 15 | 160 | Male | 6.96 | 8 | 115 |
| Female | 6.33 | 7 | 111 | Female | 5.01 | 5 | 100 |
| Total | 15.71 | 22 | 140 | Total | 11.98 | 13 | 109 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 5.10 | 6 | 118 | Male | 3.28 | 3 | NC* |
| Female | 1.39 | 0 | NC* | | | | |
| Total | 6.48 | 6 | 93 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 7.70 | 9 | 117 | Male | 2.07 | 3 | NC* |
| Female | 6.93 | 5 | 72 | Female | 6.01 | 6 | 100 |
| Total | 14.63 | 14 | 96 | Total | 8.08 | 9 | 111 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and I | <u> Uterus, NOS</u> | | |
| Male | 4.03 | 1 | NC* | | | | |
| Female | 1.91 | 5 | 262 | Female | 19.47 | 20 | 103 |
| Total | 5.94 | 6 | 101 | | | | |
| Lung and Bronchus | <u>s</u> | | | All Sites / Types | | | |
| Male | 50.80 | 58 | 114 | Male | 325.68 | 352 | 108 |
| Female | 45.78 | 44 | 96 | Female | 338.34 | 380 | 112 #+ |
| Total | 96.58 | 102 | 106 | Total | 664.03 | 732 | 110 ~+ |

StoughtonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Exp | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|------------------|-------|------------|-----|----------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Si | <u>kin</u> | | |
| Male | 18.49 | 23 | 124 | Male | 13.59 | 7 | 52 |
| Female | 7.07 | 7 | 99 | Female | 10.84 | 16 | 148 |
| Total | 25.56 | 30 | 117 | Total | 24.43 | 23 | 94 |

| Brain and Other Ne | rvous System | | | Multiple Myeloma | | | |
|---------------------|-----------------|------|-----|---------------------|----------------|-----|--------|
| Male | 6.16 | 7 | 114 | Male | 3.83 | 2 | NC* |
| Female | 5.17 | 5 | 97 | Female | 3.55 | 3 | NC* |
| Total | 11.33 | 12 | 106 | Total | 7.38 | 5 | 68 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | <u>/mphoma</u> | | |
| Male | 0.93 | 0 | NC* | Male | 15.37 | 25 | 163 #+ |
| Female | 122.72 | 141 | 115 | Female | 14.10 | 15 | 106 |
| Total | 123.65 | 141 | 114 | Total | 29.46 | 40 | 136 |
| Cervix Uteri | | | | Oral Cavity & Phar | <u>ynx</u> | | |
| | | | | Male | 12.02 | 10 | 83 |
| Female | 6.61 | 7 | 106 | Female | 6.01 | 7 | 117 |
| | | | | Total | 18.02 | 17 | 94 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 46.69 | 50 | 107 | | | | |
| Female | 45.98 | 45 | 98 | Female | 14.20 | 11 | 77 |
| Total | 92.67 | 95 | 103 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 6.97 | 5 | 72 | Male | 8.35 | 3 | NC* |
| Female | 2.18 | 0 | NC* | Female | 9.00 | 11 | 122 |
| Total | 9.15 | 5 | 55 | Total | 17.35 | 14 | 81 |
| Hodgkin's Disease | (Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 2.83 | 7 | 248 | Male | 122.61 | 122 | 100 |
| Female | 2.41 | 1 | NC* | | | | |
| Total | 5.24 | 8 | 153 | | | | |
| Kidney & Renal Pel | <u>vis</u> | | | Stomach | | | |
| Male | 11.51 | 8 | 70 | Male | 8.08 | 5 | 62 |
| Female | 7.27 | 13 | 179 | Female | 4.99 | 5 | 100 |
| Total | 18.78 | 21 | 112 | Total | 13.07 | 10 | 77 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 6.30 | 1 | NC* | Male | 4.48 | 4 | NC* |
| Female | 1.67 | 1 | NC* | | | | |
| Total | 7.97 | 2 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 9.34 | 9 | 96 | Male | 2.73 | 4 | NC* |
| Female | 7.61 | 3 | NC* | Female | 7.96 | 4 | NC* |
| Total | 16.95 | 12 | 71 | Total | 10.68 | 8 | 75 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and I | Uterus, NOS | | |
| Male | 4.96 | 3 | NC* | | | | |
| Female | 1.99 | 1 | NC* | Female | 23.40 | 19 | 81 |
| Total | 6.95 | 4 | NC* | | | | |
| Lung and Bronchus | <u>s</u> | | | All Sites / Types | | | |
| Male | 60.31 | 49 | 81 | Male | 390.96 | 372 | 95 |
| Female | 51.79 | 59 | 114 | Female | 383.77 | 407 | 106 |
| Total | 112.10 | 108 | 96 | Total | 774.73 | 779 | 101 |
| | | | | | | | |

Stow

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|------------------------|------------|------------|------|----------------------|------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 2.85 | 1 | NC* | Male | 2.45 | 3 | NC* |
| Female | 0.94 | 0 | NC* | Female | 1.78 | 5 | 281 |
| Total | 3.79 | 1 | NC* | Total | 4.23 | 8 | 189 |
| Brain and Other Nervo | - | | | Multiple Myeloma | | | |
| Male | 1.14 | 1 | NC* | Male | 0.64 | 0 | NC* |
| Female | 0.83 | 3 | NC* | Female | 0.51 | 0 | NC* |
| Total | 1.97 | 4 | NC* | Total | 1.15 | 0 | NC* |
| Breast | | • | | Non-Hodgkin('s) Lyn | - | | |
| Male | 0.15 | 0 | NC* | Male | 2.64 | 4 | NC* |
| Female | 20.50 | 28 | 137 | Female | 2.02 | 0 | NC* |
| Total | 20.65 | 28 | 136 | Total | 4.67 | 4 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyn | | • | |
| | | | | Male | 2.31 | 0 | NC* |
| Female | 1.13 | 0 | NC* | Female | 0.94 | 2 | NC* |
| | | | | Total | 3.24 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 7.35 | 8 | 109 | | | • | |
| Female | 6.15 | 5 | 81 | Female | 2.31 | 0 | NC* |
| Total | 13.51 | 13 | 96 | _ | | | |
| <u>Esophagus</u> | 4.00 | • | | <u>Pancreas</u> | 4.00 | • | |
| Male | 1.22 | 0 | NC* | Male | 1.38 | 0 | NC* |
| Female | 0.29 | 0 | NC* | Female | 1.18 | 2 | NC* |
| Total | 1.52 | 0 | NC* | Total | 2.56 | 2 | NC* |
| Hodgkin's Disease (Ho | | | | <u>Prostate</u> | | 40 | |
| Male | 0.51 | 0 | NC* | Male | 20.94 | 19 | 91 |
| Female | 0.38 | 1 | NC* | | | | |
| Total | 0.89 | 1 | NC* | 0 , 1 | | | |
| Kidney & Renal Pelvis | = | 0 | NOt | <u>Stomach</u> | 4.00 | • | NO* |
| Male | 2.08 | 0 | NC* | Male | 1.30 | 0 | NC* |
| Female | 1.10 | 2 | NC* | Female | 0.66 | 1 | NC* |
| Total | 3.18 | 2 | NC* | Total | 1.97 | 1 | NC* |
| <u>Larynx</u> | 4.40 | 0 | NO* | <u>Testis</u> | 0.74 | 0 | NO* |
| Male | 1.16 | 0 | NC* | Male | 0.71 | 0 | NC* |
| Female | 0.26 | 0 | NC* | | | | |
| Total | 1.42 | 0 | NC* | - | | | |
| <u>Leukemia</u> | 4.00 | 0 | NOT | <u>Thyroid</u> | 0.54 | • | NO* |
| Male | 1.62 | 2 | NC* | Male | 0.51 | 0 | NC* |
| Female | 1.17 | 0 | NC* | Female | 1.38 | 0 | NC* |
| Total | 2.79 | 2 | NC* | Total | 1.89 | 0 | NC* |
| Liver and Intrahepatic | | 0 | N/O* | Uteri, Corpus and Ut | erus, NOS | | |
| Male | 0.90 | 0 | NC* | F- 1 | 2.04 | , | N10+ |
| Female | 0.27 | 0 | NC* | Female | 3.94 | 1 | NC* |
| Total | 1.17 | 0 | NC* | AU 0'' / = | | | |
| Lung and Bronchus | 0.04 | 7 | 74 | All Sites / Types | 05.05 | 40 | 70 " |
| Male | 9.84 | 7 | 71 | Male | 65.85 | 46 | 70 #-> |

| Female | 7.49 | 6 | 80 | Female | 59.16 | 56 | 95 > |
|--------|-------|----|----|--------|--------|-----|--------|
| Total | 17.33 | 13 | 75 | Total | 125.01 | 102 | 82 #-> |

SturbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Exp | Obs | SIR | | <u>Exp</u> | Obs | SIR |
|-----------------------|----------------|------|-----|---------------------|------------|-----|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 5.32 | 8 | 150 | Male | 3.96 | 3 | NC* |
| Female | 1.86 | 1 | NC* | Female | 2.96 | 3 | NC* |
| Total | 7.18 | 9 | 125 | Total | 6.92 | 6 | 87 |
| Brain and Other Nerv | vous System | | | Multiple Myeloma | | | |
| Male | 1.79 | 0 | NC* | Male | 1.12 | 1 | NC* |
| Female | 1.43 | 0 | NC* | Female | 0.95 | 1 | NC* |
| Total | 3.22 | 0 | NC* | Total | 2.07 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma_ | | |
| Male | 0.27 | 0 | NC* | Male | 4.43 | 11 | 248 #+ |
| Female | 33.83 | 26 | 77 | Female | 3.79 | 6 | 158 |
| Total | 34.10 | 26 | 76 | Total | 8.22 | 17 | 207 ~+ |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 3.58 | 3 | NC* |
| Female | 1.81 | 2 | NC* | Female | 1.63 | 1 | NC* |
| | | | | Total | 5.22 | 4 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 13.46 | 13 | 97 | | | | |
| Female | 12.09 | 18 | 149 | Female | 3.89 | 4 | NC* |
| Total | 25.55 | 31 | 121 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 2.05 | 0 | NC* | Male | 2.43 | 1 | NC* |
| Female | 0.57 | 0 | NC* | Female | 2.36 | 2 | NC* |
| Total | 2.63 | 0 | NC* | Total | 4.79 | 3 | NC* |
| Hodgkin's Disease (H | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.77 | 0 | NC* | Male | 35.95 | 31 | 86 |
| Female | 0.65 | 0 | NC* | | | | |
| Total | 1.43 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | Stomach | | | |
| Male | 3.40 | 3 | NC* | Male | 2.34 | 4 | NC* |
| Female | 1.98 | 2 | NC* | Female | 1.29 | 1 | NC* |
| Total | 5.38 | 5 | 93 | Total | 3.63 | 5 | 138 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.87 | 1 | NC* | Male | 1.13 | 1 | NC* |
| Female | 0.46 | 0 | NC* | | | | |
| Total | 2.33 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.72 | 5 | 184 | Male | 0.78 | 0 | NC* |
| Female | 2.06 | 1 | NC* | Female | 2.18 | 2 | NC* |
| Total | 4.78 | 6 | 125 | Total | 2.96 | 2 | NC* |
| Liver and Intrahepati | ic Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |

| Male | 1.47 | 1 | NC* | | | | |
|-------------------|-------|----|-----|-------------------|--------|-----|-----|
| Female | 0.53 | 2 | NC* | Female | 6.50 | 7 | 108 |
| Total | 1.99 | 3 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 17.51 | 18 | 103 | Male | 113.65 | 112 | 99 |
| Female | 14.06 | 4 | NC* | Female | 104.13 | 88 | 85 |
| Total | 31.58 | 22 | 70 | Total | 217.78 | 200 | 92 |

Sudbury Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|----------------|------------|------------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 9.41 | 9 | 96 | Male | 7.57 | 10 | 132 |
| Female | 2.89 | 3 | NC* | Female | 5.40 | 10 | 185 |
| Total | 12.30 | 12 | 98 | Total | 12.97 | 20 | 154 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 3.47 | 2 | NC* | Male | 2.06 | 3 | NC* |
| Female | 2.53 | 1 | NC* | Female | 1.59 | 1 | NC* |
| Total | 6.00 | 3 | NC* | Total | 3.65 | 4 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.50 | 0 | NC* | Male | 8.21 | 6 | 73 |
| Female | 63.90 | 80 | 125 | Female | 6.28 | 2 | NC* |
| Total | 64.41 | 80 | 124 | Total | 14.49 | 8 | 55 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 7.18 | 3 | NC* |
| Female | 3.37 | 2 | NC* | Female | 2.92 | 4 | NC* |
| | | | | Total | 10.10 | 7 | 69 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 24.25 | 15 | 62 | | | | |
| Female | 18.48 | 16 | 87 | Female | 7.21 | 8 | 111 |
| Total | 42.73 | 31 | 73 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 3.98 | 2 | NC* | Male | 4.49 | 8 | 178 |
| Female | 0.90 | 2 | NC* | Female | 3.62 | 6 | 166 |
| Total | 4.87 | 4 | NC* | Total | 8.11 | 14 | 173 |
| Hodgkin's Disease (| Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 1.45 | 0 | NC* | Male | 70.38 | 59 | 84 |
| Female | 1.13 | 1 | NC* | | | | |
| Total | 2.57 | 1 | NC* | | | | |
| Kidney & Renal Pelv | <u>ris</u> | | | <u>Stomach</u> | | | |
| Male | 6.52 | 3 | NC* | Male | 4.21 | 6 | 142 |
| Female | 3.51 | 2 | NC* | Female | 1.96 | 2 | NC* |
| Total | 10.04 | 5 | 50 | Total | 6.18 | 8 | 130 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 3.73 | 3 | NC* | Male | 2.00 | 3 | NC* |
| Female | 0.87 | 0 | NC* | | | | |
| Total | 4.60 | 3 | NC* | | | | |

| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
|-----------------------------------|-------|----|-------|-------------------------------|--------|-----|-------|
| Male | 4.98 | 5 | 100 | Male | 1.54 | 2 | NC* |
| Female | 3.53 | 0 | NC* | Female | 4.08 | 6 | 147 |
| Total | 8.51 | 5 | 59 | Total | 5.61 | 8 | 143 |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 2.86 | 3 | NC* | | | | |
| Female | 0.83 | 0 | NC* | Female | 12.51 | 8 | 64 |
| Total | 3.68 | 3 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 32.81 | 17 | 52 ~- | Male | 214.60 | 172 | 80 ~- |
| Female | 24.32 | 24 | 99 | Female | 183.54 | 190 | 104 |
| Total | 57.13 | 41 | 72 #- | Total | 398.14 | 362 | 91 |

Sunderland
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------------------------|-------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 1.40 | 0 | NC* | Male | 1.27 | 2 | NC* |
| Female | 0.51 | 0 | NC* | Female | 1.09 | 0 | NC* |
| Total | 1.90 | 0 | NC* | Total | 2.36 | 2 | NC* |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 0.62 | 0 | NC* | Male | 0.30 | 0 | NC* |
| Female | 0.49 | 0 | NC* | Female | 0.26 | 1 | NC* |
| Total | 1.11 | 0 | NC* | Total | 0.56 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | <u>nphoma</u> | | |
| Male | 0.08 | 0 | NC* | Male | 1.43 | 3 | NC* |
| Female | 10.23 | 15 | 147 | Female | 1.15 | 1 | NC* |
| Total | 10.31 | 15 | 146 | Total | 2.58 | 4 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>1X</u> | | |
| | | | | Male | 1.02 | 0 | NC* |
| Female | 0.77 | 0 | NC* | Female | 0.47 | 0 | NC* |
| | | | | Total | 1.49 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 3.58 | 2 | NC* | | | | |
| Female | 3.32 | 3 | NC* | Female | 1.24 | 1 | NC* |
| Total | 6.91 | 5 | 72 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.53 | 0 | NC* | Male | 0.65 | 2 | NC* |
| Female | 0.16 | 0 | NC* | Female | 0.63 | 0 | NC* |
| Total | 0.69 | 0 | NC* | Total | 1.28 | 2 | NC* |
| Hodgkin's Disease (Hodgkin Lymphoma) | | | | <u>Prostate</u> | | | |
| Male | 0.39 | 0 | NC* | Male | 8.88 | 12 | 135 |
| Female | 0.33 | 0 | NC* | | | | |
| Total | 0.72 | 0 | NC* | | | | |
| Kidney & Renal Pelv | | | | <u>Stomach</u> | | | |
| Male | 0.97 | 0 | NC* | Male | 0.63 | 1 | NC* |
| Female | 0.56 | 1 | NC* | Female | 0.37 | 1 | NC* |

| Total | 1.53 | 1 | NC* | Total | 1.00 | 2 | NC* | |
|-----------------------------------|------|---|-----|-------------------------------|-------|----|------|--|
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 0.49 | 1 | NC* | Male | 0.76 | 0 | NC* | |
| Female | 0.12 | 0 | NC* | | | | | |
| Total | 0.61 | 1 | NC* | | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | | |
| Male | 0.85 | 1 | NC* | Male | 0.32 | 0 | NC* | |
| Female | 0.64 | 0 | NC* | Female | 1.02 | 1 | NC* | |
| Total | 1.49 | 1 | NC* | Total | 1.34 | 1 | NC* | |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 0.41 | 0 | NC* | | | | | |
| Female | 0.15 | 0 | NC* | Female | 1.79 | 2 | NC* | |
| Total | 0.56 | 0 | NC* | | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | | |
| Male | 4.56 | 4 | NC* | Male | 31.38 | 30 | 96 > | |
| Female | 3.67 | 1 | NC* | Female | 31.13 | 30 | 96 > | |
| Total | 8.23 | 5 | 61 | Total | 62.50 | 60 | 96 | |

Sutton
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------------------|----------------|------------|------------------|----------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.40 | 1 | NC* | Male | 3.53 | 2 | NC* |
| Female | 1.34 | 1 | NC* | Female | 2.52 | 3 | NC* |
| Total | 5.74 | 2 | NC* | Total | 6.04 | 5 | 83 |
| Brain and Other Nervous System | | | Multiple Myeloma | | | | |
| Male | 1.62 | 2 | NC* | Male | 0.94 | 1 | NC* |
| Female | 1.21 | 1 | NC* | Female | 0.71 | 4 | NC* |
| Total | 2.83 | 3 | NC* | Total | 1.66 | 5 | 302 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.22 | 0 | NC* | Male | 3.88 | 3 | NC* |
| Female | 28.03 | 16 | 57 #- | Female | 2.92 | 2 | NC* |
| Total | 28.25 | 16 | 57 #- | Total | 6.81 | 5 | 73 |
| Cervix Uteri | | | | Oral Cavity & Pharys | <u>1X</u> | | |
| | | | | Male | 3.24 | 2 | NC* |
| Female | 1.62 | 1 | NC* | Female | 1.30 | 0 | NC* |
| | | | | Total | 4.54 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 11.18 | 7 | 63 | | | | |
| Female | 8.77 | 6 | 68 | Female | 3.23 | 2 | NC* |
| Total | 19.95 | 13 | 65 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.76 | 2 | NC* | Male | 2.06 | 2 | NC* |
| Female | 0.42 | 1 | NC* | Female | 1.69 | 2 | NC* |
| Total | 2.17 | 3 | NC* | Total | 3.75 | 4 | NC* |
| Hodgkin's Disease (I | Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.73 | 2 | NC* | Male | 30.00 | 26 | 87 |
| | | | | | | | |

| Female | 0.60 | 2 | NC* | | | | | |
|--------------------------|---------------|----|-----|-------------------------------|--------|-----|-------|--|
| Total | 1.33 | 4 | NC* | | | | | |
| Kidney & Renal Pelv | <u>ris</u> | | | Stomach | | | | |
| Male | 2.97 | 3 | NC* | Male | 2.00 | 3 | NC* | |
| Female | 1.55 | 2 | NC* | Female | 0.94 | 1 | NC* | |
| Total | 4.52 | 5 | 111 | Total | 2.94 | 4 | NC* | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 1.63 | 2 | NC* | Male | 1.09 | 2 | NC* | |
| Female | 0.36 | 0 | NC* | | | | | |
| Total | 1.99 | 2 | NC* | | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | | |
| Male | 2.38 | 1 | NC* | Male | 0.73 | 0 | NC* | |
| Female | 1.68 | 3 | NC* | Female | 2.01 | 2 | NC* | |
| Total | 4.05 | 4 | NC* | Total | 2.74 | 2 | NC* | |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 1.28 | 1 | NC* | | | | | |
| Female | 0.39 | 0 | NC* | Female | 5.33 | 6 | 113 | |
| Total | 1.67 | 1 | NC* | | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | | |
| Male | 14.42 | 14 | 97 | Male | 96.30 | 79 | 82 > | |
| Female | 10.62 | 11 | 104 | Female | 82.79 | 71 | 86 | |
| Total | 25.04 | 25 | 100 | Total | 179.09 | 150 | 84 #- | |

Swampscott
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Ехр | <u>Obs</u> | SIR | | <u>Exp</u> | Obs | SIR |
|----------------------|------------|------------|-----|---------------------|---------------|-----|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 11.76 | 10 | 85 | Male | 7.93 | 20 | 252 ^+ |
| Female | 4.48 | 9 | 201 | Female | 6.28 | 3 | NC* |
| Total | 16.24 | 19 | 117 | Total | 14.21 | 23 | 162 #+ |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 3.43 | 3 | NC* | Male | 2.39 | 2 | NC* |
| Female | 3.04 | 5 | 165 | Female | 2.22 | 3 | NC* |
| Total | 6.47 | 8 | 124 | Total | 4.61 | 5 | 109 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>mphoma</u> | | |
| Male | 0.57 | 0 | NC* | Male | 9.06 | 5 | 55 |
| Female | 73.54 | 83 | 113 | Female | 8.65 | 6 | 69 |
| Total | 74.10 | 83 | 112 | Total | 17.71 | 11 | 62 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 7.07 | 1 | NC* |
| Female | 3.67 | 1 | NC* | Female | 3.67 | 3 | NC* |
| | | | | Total | 10.74 | 4 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 29.31 | 22 | 75 | | | | |
| Female | 29.38 | 27 | 92 | Female | 8.42 | 12 | 142 |
| Total | 58.69 | 49 | 83 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |

| Male | 4.24 | 6 | 141 | Male | 5.20 | 6 | 115 |
|--------------------------|-----------------|------------|-----|---------------------|--------------------|-----|--------|
| Female | 1.39 | 1 | NC* | Female | 5.73 | 5 | 87 |
| Total | 5.63 | 7 | 124 | Total | 10.92 | 11 | 101 |
| Hodgkin's Disease (I | Hodgkin Lymphor | <u>na)</u> | | <u>Prostate</u> | | | |
| Male | 1.36 | 0 | NC* | Male | 74.72 | 101 | 135 ~+ |
| Female | 1.28 | 1 | NC* | | | | |
| Total | 2.65 | 1 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |
| Male | 6.91 | 12 | 174 | Male | 5.08 | 3 | NC* |
| Female | 4.42 | 6 | 136 | Female | 3.15 | 5 | 159 |
| Total | 11.34 | 18 | 159 | Total | 8.24 | 8 | 97 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 3.77 | 1 | NC* | Male | 1.92 | 1 | NC* |
| Female | 1.01 | 0 | NC* | | | | |
| Total | 4.78 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 5.56 | 5 | 90 | Male | 1.42 | 2 | NC* |
| Female | 4.62 | 5 | 108 | Female | 4.28 | 1 | NC* |
| Total | 10.18 | 10 | 98 | Total | 5.70 | 3 | NC* |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and L | <u>Iterus, NOS</u> | | |
| Male | 2.97 | 4 | NC* | | | | |
| Female | 1.25 | 1 | NC* | Female | 14.16 | 15 | 106 |
| Total | 4.22 | 5 | 118 | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 37.21 | 28 | 75 | Male | 237.35 | 249 | 105 |
| Female | 32.14 | 37 | 115 | Female | 233.82 | 250 | 107 |
| Total | 69.35 | 65 | 94 | Total | 471.17 | 499 | 106 |

SwanseaExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|------------|---------------------|---------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 11.89 | 6 | 50 | Male | 8.47 | 4 | NC* |
| Female | 4.31 | 2 | NC* | Female | 6.30 | 2 | NC* |
| Total | 16.20 | 8 | 49 #- | Total | 14.78 | 6 | 41 #- |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 3.75 | 4 | NC* | Male | 2.45 | 4 | NC* |
| Female | 3.02 | 4 | NC* | Female | 2.17 | 2 | NC* |
| Total | 6.77 | 8 | 118 | Total | 4.62 | 6 | 130 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>nphoma</u> | | |
| Male | 0.59 | 0 | NC* | Male | 9.57 | 8 | 84 |
| Female | 73.91 | 65 | 88 | Female | 8.44 | 5 | 59 |
| Total | 74.50 | 65 | 87 | Total | 18.02 | 13 | 72 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 7.61 | 5 | 66 |
| Female | 3.73 | 5 | 134 | Female | 3.63 | 2 | NC* |
| | | | | Total | 11.24 | 7 | 62 |

| Male 29.91 28 94 Female 28.10 20 71 Female 8.45 8 95 Total 58.01 48 83 95 Esophagus Male 4.45 5 112 Male 5.35 4 NC* Female 1.33 2 NC* Female 5.49 10 182 Total 5.79 7 121 Total 10.84 14 129 Hodgkin's Disease (Hotbyin Lymphoma) Prostate Total 78.32 93 118 129 13 NC* Male 78.32 93 118 129 13 NC* Male 78.32 93 118 129 13 NC* 120 | Colon / Rectum | | | | <u>Ovary</u> | | | | |
|--|--|-----------------|------------|-----|---------------------|--------------------|-----|-------|--|
| Feather Septiments Pancreas Esophagus Pancreas Male 4.45 5 112 Male 5.35 4 NC* Female 1.33 2 NC* Female 5.49 10 182 Total 5.79 7 121 Total 10.84 14 128 Prostate Male 1.59 2 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Kidney & Renal Petvis Stomach Stomach Stomach Male 7.28 5 69 Male 5.20 3 NC* Female 4.31 3 NC* Female 3.02 0 NC* <th col<="" td=""><td>Male</td><td>29.91</td><td>28</td><td>94</td><td></td><td></td><td></td><td></td></th> | <td>Male</td> <td>29.91</td> <td>28</td> <td>94</td> <td></td> <td></td> <td></td> <td></td> | Male | 29.91 | 28 | 94 | | | | |
| Feacheage Male 4.45 5 112 Male 5.35 4 NC° Female 1.33 2 NC° Female 5.49 10 182 Total 5.79 7 121 Total 10.84 43 129 Hodgkin's Disease (Hoty) Lymphome Prostate Male 1.29 3 NC° Male 78.32 93 119 Female 1.29 3 NC° Stomach 93 119 Female 1.29 3 NC° Stomach 3 NC° Male 7.28 5 69 Male 5.20 3 NC° Female 4.39 4 NC° Female 3.02 1 NC° Female 4.01 3 NC° Male 2.36 0 NC° Female 4.01 3 NC° Male 4.32 | Female | 28.10 | 20 | 71 | Female | 8.45 | 8 | 95 | |
| Male 4.45 5 112 Male 5.35 4 NC* Female 1.33 2 NC* Female 5.49 10 182 Total 5.79 7 121 Total 10.84 14 129 Male 1.59 2 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Kidney & Real Pelvis 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Female 4.01 3 NC* Male 2.36 0 NC* Female 4.01 3 | Total | 58.01 | 48 | 83 | | | | | |
| Female 1.33 2 NC* Female 5.49 10 12 Total 5.79 7 121 Total 10.84 14 129 Hodgkin's Disease (Hodgkin Lymphoma) Prostate Male 1.59 2 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Kidney & Renal Pevis Stomach Kidney & Renal Pevis Stomach Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Female 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 1.62 1 NC* Leukemia | <u>Esophagus</u> | | | | <u>Pancreas</u> | | | | |
| Total Total Total 10.84 10.84 14 129 Hodgkin's Disease (Hodgkin's Disease (Hodgkin's Disease (Hodgkin's Disease) (Hodgki | Male | 4.45 | 5 | 112 | Male | 5.35 | 4 | NC* | |
| Prostate Male 1.59 2 NC* Male 78.32 93 119 Female 1.29 3 NC* ———————————————————————————————————— | Female | 1.33 | 2 | NC* | Female | 5.49 | 10 | 182 | |
| Male 1.59 2 NC* Male 78.32 93 119 Female 1.29 3 NC* Male 78.32 93 119 Total 2.28 5 174 Total 2.20 3 NC* Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Eemale 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Female 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female < | Total | 5.79 | 7 | 121 | Total | 10.84 | 14 | 129 | |
| Female Total 1.29 3 NC* Total 2.88 5 174 Stomach Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Male 4.01 3 NC* Male 2.36 0 NC* Female 10.2 1 NC* Male 2.36 0 NC* Female 10.2 1 NC* Male 2.36 0 NC* Female 10.2 1 NC* Male 3.60 NC* NC* Female 5.82 4 NC* Male 4.37 3 NC* Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 5 NC* Female 4.37 3 NC* Liver and Intrahepate: In Ducts NC* Female 3.14 1 1 7 7 < | Hodgkin's Disease | (Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | | |
| Total 2.88 5 174 Kidney & Renal Pelvis Stomach Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Larynx Testis Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Female 5.03 4 NC* Male 1.62 1 NC* Leukemia Thyroid Thyroid 1 NC* NC* Female 5.82 4 NC* Female 4.37 3 NC* Female 4.53 2 NC* Female 14.27 10 7 Male 3.14< | Male | 1.59 | 2 | NC* | Male | 78.32 | 93 | 119 | |
| Kidney & Renal Pelvs Stomach Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Female 1.02 1 NC* Thyroid 1 NC* Leukemia 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Liver and Intrahepatise Ducts Uteric Corpus and Uteric Corpus a | Female | 1.29 | 3 | NC* | | | | | |
| Male 7.28 5 69 Male 5.20 3 NC* Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Larynx Testis Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Leukemia Thyroid Male 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Liver and Intrahepatic Bib Ducts Uteri, Corpus and Uterus, NOS Female 1.21 0 NC* Female 14.27 10 70 70 Total | Total | 2.88 | 5 | 174 | | | | | |
| Female 4.39 4 NC* Female 3.02 1 NC* Total 11.67 9 77 Total 8.22 4 NC* Larynx Testis Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Total 5.03 4 NC* Thyroid Thyroid Thyroid NC* | Kidney & Renal Pe | <u>lvis</u> | | | <u>Stomach</u> | | | | |
| Total 11.67 9 77 Total 8.22 4 NC* Larynx Testis Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Male 2.36 0 NC* Total 5.03 4 NC* Teyroid Teyroid NC* NC*< | Male | 7.28 | 5 | 69 | Male | 5.20 | 3 | NC* | |
| Larynx Testis Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* ———————————————————————————————————— | Female | 4.39 | 4 | NC* | Female | 3.02 | 1 | NC* | |
| Male 4.01 3 NC* Male 2.36 0 NC* Female 1.02 1 NC* Image: Comparison of the comparison of t | Total | 11.67 | 9 | 77 | Total | 8.22 | 4 | NC* | |
| Female Total 1.02 1 NC* Total 5.03 4 NC* Eukemia Thyroid Male 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Utteri, Corpus and Uterus, NOS Male 3.14 2 NC* Female 14.27 10 70 70 Total 4.35 2 NC* Female 14.27 10 70 70 Total 4.35 2 NC* All Sites / Types 70 <td><u>Larynx</u></td> <td></td> <td></td> <td></td> <td><u>Testis</u></td> <td></td> <td></td> <td></td> | <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Total 5.03 4 NC* Leukemia Thyroid Male 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 3.14 2 NC* Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types 247.83 240 97 Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78.^ | Male | 4.01 | 3 | NC* | Male | 2.36 | 0 | NC* | |
| Leukemia Thyroid Male 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 3.14 2 NC* Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Female | 1.02 | 1 | NC* | | | | | |
| Male 5.82 4 NC* Male 1.62 1 NC* Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Male 3.14 2 NC* Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Total | 5.03 | 4 | NC* | | | | | |
| Female 4.53 2 NC* Female 4.37 3 NC* Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Male 3.14 2 NC* V Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | <u>Leukemia</u> | | | | Thyroid | | | | |
| Total 10.36 6 58 Total 5.99 4 NC* Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 3.14 2 NC* Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Lung and Bronchus All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Male | 5.82 | 4 | NC* | Male | 1.62 | 1 | NC* | |
| Liver and Intrahepatic Bile Ducts Uteri, Corpus and Uterus, NOS Male 3.14 2 NC* Female 14.27 10 70 Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Lung and Bronchus All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Female | 4.53 | 2 | NC* | Female | 4.37 | 3 | NC* | |
| Male 3.14 2 NC* Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Total | 10.36 | 6 | 58 | Total | 5.99 | 4 | NC* | |
| Female 1.21 0 NC* Female 14.27 10 70 Total 4.35 2 NC* All Sites / Types Lung and Bronchus All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Liver and Intrahepa | atic Bile Ducts | | | Uteri, Corpus and I | <u>Jterus, NOS</u> | | | |
| Total 4.35 2 NC* All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Male | 3.14 | 2 | NC* | | | | | |
| All Sites / Types Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Female | 1.21 | 0 | NC* | Female | 14.27 | 10 | 70 | |
| Male 38.44 45 117 Male 247.83 240 97 Female 31.61 23 73 Female 231.06 181 78 ^- | Total | 4.35 | 2 | NC* | | | | | |
| Female 31.61 23 73 Female 231.06 181 78 ^- | Lung and Bronchu | <u>s</u> | | | All Sites / Types | | | | |
| | Male | 38.44 | 45 | 117 | Male | 247.83 | 240 | 97 | |
| Total 70.05 68 97 Total 478.89 421 88 ~- | Female | 31.61 | 23 | 73 | Female | 231.06 | 181 | 78 ^- | |
| | Total | 70.05 | 68 | 97 | Total | 478.89 | 421 | 88 ~- | |

TauntonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|-------------|------------|------------|---------------------|---------------|------------|-------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 31.28 | 28 | 90 | Male | 22.73 | 14 | 62 |
| Female | 13.14 | 17 | 129 | Female | 19.61 | 15 | 77 |
| Total | 44.41 | 45 | 101 | Total | 42.34 | 29 | 68 #- |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 10.57 | 11 | 104 | Male | 6.40 | 10 | 156 |
| Female | 9.56 | 4 | NC* | Female | 6.43 | 8 | 124 |
| Total | 20.13 | 15 | 75 | Total | 12.84 | 18 | 140 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyr | <u>nphoma</u> | | |
| Male | 1.55 | 2 | NC* | Male | 26.03 | 26 | 100 |
| Female | 215.48 | 229 | 106 | Female | 25.86 | 30 | 116 |

268

| Total | 217.03 | 231 | 106 | Total | 51.88 | 56 | 108 |
|--------------------|------------------------|------|--------|--------------------|--------------------|------|--------|
| Cervix Uteri | | | | Oral Cavity & Phar | <u>ynx</u> | | |
| | | | | Male | 19.76 | 33 | 167 ~+ |
| Female | 11.99 | 12 | 100 | Female | 10.73 | 10 | 93 |
| | | | | Total | 30.50 | 43 | 141 #+ |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 78.63 | 86 | 109 | | | | |
| Female | 86.24 | 86 | 100 | Female | 25.19 | 19 | 75 |
| Total | 164.87 | 172 | 104 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 11.49 | 13 | 113 | Male | 13.98 | 19 | 136 |
| Female | 4.06 | 4 | NC* | Female | 16.75 | 18 | 107 |
| Total | 15.55 | 17 | 109 | Total | 30.73 | 37 | 120 |
| Hodgkin's Disease | <u>(Hodgkin Lympho</u> | oma) | | Prostate | | | |
| Male | 4.98 | 5 | 100 | Male | 200.60 | 172 | 86 #- |
| Female | 4.63 | 4 | NC* | | | | |
| Total | 9.61 | 9 | 94 | | | | |
| Kidney & Renal Pe | <u>elvis</u> | | | Stomach | | | |
| Male | 19.13 | 21 | 110 | Male | 13.67 | 20 | 146 |
| Female | 12.95 | 22 | 170 #+ | Female | 9.42 | 10 | 106 |
| Total | 32.07 | 43 | 134 | Total | 23.09 | 30 | 130 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 10.29 | 17 | 165 | Male | 8.00 | 9 | 113 |
| Female | 2.86 | 4 | NC* | | | | |
| Total | 13.15 | 21 | 160 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 16.12 | 22 | 136 | Male | 4.59 | 0 | NC* |
| Female | 14.21 | 16 | 113 | Female | 14.60 | 13 | 89 |
| Total | 30.33 | 38 | 125 | Total | 19.18 | 13 | 68 |
| Liver and Intrahep | atic Bile Ducts | | | Uteri, Corpus and | <u>Uterus, NOS</u> | | |
| Male | 8.21 | 6 | 73 | | | | |
| Female | 3.69 | 1 | NC* | Female | 40.41 | 37 | 92 |
| Total | 11.90 | 7 | 59 | | | | |
| Lung and Bronchu | <u>ıs</u> | | | All Sites / Types | | | |
| Male | 100.03 | 140 | 140 ^+ | Male | 651.56 | 697 | 107 |
| Female | 91.91 | 99 | 108 | Female | 690.72 | 697 | 101 |
| Total | 191.94 | 239 | 125 ~+ | Total | 1342.28 | 1394 | 104 |

TempletonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------|-------------|------------|-----|------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.79 | 3 | NC* | Male | 3.57 | 6 | 168 |
| Female | 1.62 | 2 | NC* | Female | 2.48 | 3 | NC* |
| Total | 6.41 | 5 | 78 | Total | 6.05 | 9 | 149 |
| Brain and Other Ne | vous System | | | Multiple Myeloma | | | |
| Male | 1.60 | 0 | NC* | Male | 1.01 | 2 | NC* |

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------------|--------------|------------------|-------------------|-----------------------------|----------------|------------|-----|
| | - | | ed Case Counts, w | vith Standardized Incidence | | | |
| | | | Tev | vksbury | | | |
| Total | 27.77 | 32 | 115 | Total | 190.78 | 189 | 99 |
| Female | 11.97 | 14 | 117 | Female | 88.45 | 100 | 113 |
| Male | 15.80 | 18 | 114 | Male | 102.32 | 89 | 87 |
| Lung and Bronchus | <u>3</u> | | | All Sites / Types | | | |
| Total | 1.78 | 2 | NC* | | | | |
| Female | 0.46 | 2 | NC* | Female | 5.43 | 8 | 147 |
| Male | 1.32 | 0 | NC* | | _ | | |
| Liver and Intrahepa | | | | Uteri, Corpus and I | | | |
| Total | 4.20 | 3 | NC* | Total | 2.50 | 2 | NC* |
| Female | 1.77 | 2 | NC* | Female | 1.81 | 2 | NC* |
| Male | 2.43 | 1 | NC* | Male | 0.70 | 0 | NC* |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Total | 2.08 | 0 | NC* | | | | |
| Female | 0.39 | 0 | NC* | | | | |
| Male | 1.69 | 0 | NC* | Male | 1.01 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Total | 4.74 | 2 | NC* | Total | 3.24 | 5 | 154 |
| Female | 1.68 | 1 | NC* | Female | 1.14 | 3 | NC* |
| Male | 3.06 | 1 | NC* | Male | 2.10 | 2 | NC* |
| Kidney & Renal Pel | | • | - | <u>Stomach</u> | | | |
| Total | 1.24 | 1 | NC* | | | | |
| Female | 0.55 | 1 | NC* | Maio | V2.12 | 20 | |
| Male | 0.69 | <u>oma)</u> 0 | NC* | <u>Prostate</u> Male | 32.42 | 25 | 77 |
| Hodgkin's Disease | | | INO | Prostate | 4.20 | 4 | NO |
| remale Total | 0.50 2.35 | 2 | NC* | Female Total | 2.06 4.25 | 4 | NC* |
| Female | 0.50 | 0 | NC* | Male Female | 2.19 | 2 | NC* |
| <u>Esopnagus</u> Male | 1.85 | 2 | NC* | <u>Pancreas</u> Male | 2.19 | 2 | NC* |
| Total Esophagus | 22.68 | 29 | 128 | Danarasa | | | |
| Female | 10.56 | 12 | 114 | Female | 3.27 | 4 | NC* |
| Male | 12.12 | 17 | 140 | F | 2.07 | 4 | NO* |
| Colon / Rectum | 40.40 | 47 | 440 | <u>Ovary</u> | | | |
| 0.1.15.4 | | | | Total | 4.61 | 2 | NC* |
| Female | 1.50 | 1 | NC* | Female | 1.39 | 0 | NC* |
| | | | | Male | 3.23 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phar | | | |
| Total | 28.58 | 27 | 94 | Total | 7.23 | 8 | 111 |
| Female | 28.34 | 27 | 95 | Female | 3.25 | 4 | NC* |
| Male | 0.24 | 0 | NC* | Male | 3.98 | 4 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | <u>/mphoma</u> | | |
| Total | 2.81 | 3 | NC* | Total | 1.83 | 2 | NC* |
| Female | 1.21 | 3 | NC* | Female | 0.82 | 0 | NC* |
| | | | | | | | |

Bladder, Urinary Melanoma of Skin

| Male | 16.69 | 17 | 102 | Male | 13.14 | 8 | 61 |
|---------------------|-----------------|------|--------|---------------------|-------------|-----|-----|
| Female | 5.88 | 6 | 102 | Female | 10.03 | 11 | 110 |
| Total | 22.57 | 23 | 102 | Total | 23.17 | 19 | 82 |
| Brain and Other Ne | rvous System | | | Multiple Myeloma | | | |
| Male | 6.16 | 3 | NC* | Male | 3.54 | 4 | NC* |
| Female | 4.79 | 5 | 104 | Female | 3.03 | 4 | NC* |
| Total | 10.95 | 8 | 73 | Total | 6.56 | 8 | 122 |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.86 | 1 | NC* | Male | 14.67 | 13 | 89 |
| Female | 111.46 | 112 | 100 | Female | 12.25 | 18 | 147 |
| Total | 112.33 | 113 | 101 | Total | 26.91 | 31 | 115 |
| Cervix Uteri | 112.00 | 110 | 101 | Oral Cavity & Phary | | • | 1.0 |
| OCIVIX OLEII | | | | Male | 11.77 | 12 | 102 |
| Famala | C 20 | C | 0.5 | | | | |
| Female | 6.32 | 6 | 95 | Female | 5.31 | 7 | 132 |
| | | | | Total | 17.09 | 19 | 111 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 42.62 | 39 | 92 | | | | |
| Female | 38.03 | 49 | 129 | Female | 12.93 | 14 | 108 |
| Total | 80.65 | 88 | 109 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 6.60 | 5 | 76 | Male | 7.73 | 6 | 78 |
| Female | 1.81 | 1 | NC* | Female | 7.44 | 6 | 81 |
| Total | 8.41 | 6 | 71 | Total | 15.17 | 12 | 79 |
| Hodgkin's Disease | (Hodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 2.95 | | 170 | Male | 115.60 | 109 | 94 |
| Female | 2.36 | 3 | NC* | | | | • |
| Total | 5.31 | 8 | 151 | | | | |
| Kidney & Renal Pel | | O | 101 | Stomach | | | |
| - | | 13 | 118 | | 7.42 | 7 | 94 |
| Male | 10.99 | | | Male | | 7 | |
| Female | 6.42 | 6 | 93 | Female | 4.13 | 4 | NC* |
| Total | 17.41 | 19 | 109 | Total | 11.55 | 11 | 95 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 6.07 | 8 | 132 | Male | 4.71 | 5 | 106 |
| Female | 1.49 | 1 | NC* | | | | |
| Total | 7.55 | 9 | 119 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 8.93 | 9 | 101 | Male | 2.78 | 4 | NC* |
| Female | 6.81 | 6 | 88 | Female | 7.80 | 6 | 77 |
| Total | 15.73 | 15 | 95 | Total | 10.58 | 10 | 95 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and L | Jterus. NOS | | |
| Male | 4.76 | 7 | 147 | <u></u> | | | |
| Female | 1.67 | 3 | NC* | Female | 21.18 | 16 | 76 |
| Total | 6.43 | 10 | 156 | i cinale | 21.10 | 10 | 70 |
| | | 10 | 150 | All Cites / Tomas | | | |
| Lung and Bronchus | | 00 | 450 4 | All Sites / Types | 207.40 | 204 | 404 |
| Male | 55.81 | 88 | 158 ^+ | Male | 367.49 | 381 | 104 |
| Female | 44.73 | 51 | 114 | Female | 339.20 | 359 | 106 |
| Total | 100.54 | 139 | 138 ^+ | Total | 706.69 | 740 | 105 |
| | | | | | | | |

TisburyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| Total 3.94 2 NC* Total 3.37 9 267 Brain and Other Nervous System Multiple Myeloma Male 0.80 1 NC* Male 0.55 1 N Female 0.76 0 NC* Female 0.59 1 N Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | VC* |
|---|-----|
| Female 1.22 1 NC* Female 1.54 2 NC* Total 3.94 2 NC* Total 3.37 9 267 Brain and Other Nervous System Multiple Myeloma Male 0.80 1 NC* Male 0.55 1 N Female 0.76 0 NC* Female 0.59 1 N Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | VC* |
| Total 3.94 2 NC* Total 3.37 9 267 Brain and Other Nervous System Multiple Myeloma Male 0.80 1 NC* Male 0.55 1 N Female 0.76 0 NC* Female 0.59 1 N Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | |
| Brain and Other Nervous System Multiple Myeloma Male 0.80 1 NC* Male 0.55 1 N Female 0.76 0 NC* Female 0.59 1 N Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | #+ |
| Male 0.80 1 NC* Male 0.55 1 N Female 0.76 0 NC* Female 0.59 1 N Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | |
| Female 0.76 0 NC* Female 0.59 1 NC Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | |
| Total 1.56 1 NC* Total 1.14 2 N Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | VC* |
| Breast Non-Hodgkin('s) Lymphoma Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | VC* |
| Male 0.13 0 NC* Male 2.10 2 N Female 18.17 22 121 Female 2.25 0 N | VC* |
| Female 18.17 22 121 Female 2.25 0 N | |
| | VC* |
| Total 18.30 22 120 Total 4.25 2 N | VC* |
| 10tai 10.30 22 120 10tai 4.30 2 N | VC* |
| Cervix Uteri Oral Cavity & Pharynx | |
| Male 1.64 1 N | VC* |
| Female 0.86 3 NC* Female 0.94 2 N | VC* |
| Total 2.57 3 N | VC* |
| <u>Colon / Rectum</u> <u>Ovary</u> | |
| Male 6.79 4 NC* | |
| Female 8.07 5 62 Female 2.08 4 N | VC* |
| Total 14.87 9 61 | |
| <u>Esophagus</u> <u>Pancreas</u> | |
| Male 0.99 0 NC* Male 1.20 0 N | VC* |
| Female 0.38 0 NC* Female 1.57 1 N | VC* |
| Total 1.37 0 NC* Total 2.77 1 N | VC* |
| Hodgkin's Disease (Hodgkin Lymphoma) Prostate | |
| Male 0.32 1 NC* Male 17.48 25 1 | 143 |
| Female 0.30 0 NC* | |
| Total 0.62 1 NC* | |
| Kidney & Renal Pelvis Stomach | |
| Male 1.60 2 NC* Male 1.17 1 N | VC* |
| Female 1.12 0 NC* Female 0.88 1 N | VC* |
| Total 2.73 2 NC* Total 2.05 2 N | VC* |
| <u>Larynx</u> <u>Testis</u> | |
| Male 0.88 0 NC* Male 0.44 0 N | VC* |
| Female 0.25 0 NC* | |
| Total 1.13 0 NC* | |
| <u>Leukemia</u> <u>Thyroid</u> | |
| Male 1.29 4 NC* Male 0.33 0 N | VC* |
| Female 1.21 1 NC* Female 0.97 1 N | VC* |
| Total 2.51 5 199 Total 1.30 1 N | VC* |
| <u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Uterus, NOS</u> | |
| Male 0.69 1 NC* | |
| Female 0.34 0 NC* Female 3.49 4 N | VC* |
| Total 1.03 1 NC* | |

| Lung and Bronchus | | | | All Sites / Types | | | |
|-------------------|-------|----|----|-------------------|--------|-----|-----|
| Male | 8.68 | 6 | 69 | Male | 55.22 | 64 | 116 |
| Female | 8.25 | 8 | 97 | Female | 59.82 | 59 | 99 |
| Total | 16 93 | 14 | 83 | Total | 115 05 | 123 | 107 |

TollandExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------|---------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.26 | 0 | NC* | Male | 0.18 | 0 | NC* |
| Female | 0.06 | 0 | NC* | Female | 0.10 | 0 | NC* |
| Total | 0.32 | 0 | NC* | Total | 0.29 | 0 | NC* |
| Brain and Other Nervo | ous System | | | Multiple Myeloma | | | |
| Male | 0.08 | 0 | NC* | Male | 0.05 | 0 | NC* |
| Female | 0.05 | 0 | NC* | Female | 0.03 | 0 | NC* |
| Total | 0.13 | 0 | NC* | Total | 0.09 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lym | <u>iphoma</u> | | |
| Male | 0.01 | 0 | NC* | Male | 0.20 | 1 | NC* |
| Female | 1.23 | 0 | NC* | Female | 0.13 | 0 | NC* |
| Total | 1.24 | 0 | NC* | Total | 0.34 | 1 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyn | <u>1X</u> | | |
| | | | | Male | 0.17 | 0 | NC* |
| Female | 0.06 | 0 | NC* | Female | 0.06 | 0 | NC* |
| | | | | Total | 0.23 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 0.65 | 0 | NC* | | | | |
| Female | 0.42 | 3 | NC* | Female | 0.14 | 0 | NC* |
| Total | 1.07 | 3 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.10 | 0 | NC* | Male | 0.12 | 0 | NC* |
| Female | 0.02 | 0 | NC* | Female | 0.08 | 0 | NC* |
| Total | 0.12 | 0 | NC* | Total | 0.20 | 0 | NC* |
| Hodgkin's Disease (Ho | odgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.03 | 1 | NC* | Male | 1.80 | 2 | NC* |
| Female | 0.02 | 0 | NC* | | | | |
| Total | 0.05 | 1 | NC* | | | | |
| Kidney & Renal Pelvis | | | | <u>Stomach</u> | | | |
| Male | 0.16 | 1 | NC* | Male | 0.11 | 0 | NC* |
| Female | 0.07 | 0 | NC* | Female | 0.04 | 0 | NC* |
| Total | 0.23 | 1 | NC* | Total | 0.16 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.09 | 0 | NC* | Male | 0.04 | 0 | NC* |
| Female | 0.02 | 0 | NC* | | | | |
| Total | 0.11 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.12 | 0 | NC* | Male | 0.03 | 0 | NC* |
| Female | 0.08 | 0 | NC* | Female | 0.08 | 0 | NC* |

| Total | 0.20 | 0 | NC* | Total | 0.11 | 0 | NC* |
|-----------------------|--------------|---|-----|----------------------|-----------|---|-----|
| Liver and Intrahepati | c Bile Ducts | | | Uteri, Corpus and Ut | erus, NOS | | |
| Male | 0.07 | 0 | NC* | | | | |
| Female | 0.02 | 0 | NC* | Female | 0.24 | 0 | NC* |
| Total | 0.09 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 0.86 | 0 | NC* | Male | 5.49 | 6 | 109 |
| Female | 0.50 | 0 | NC* | Female | 3.72 | 3 | NC* |
| Total | 1.36 | 0 | NC* | Total | 9.21 | 9 | 98 |

TopsfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|-------------|------------|-------|---------------------|------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 5.17 | 2 | NC* | Male | 3.53 | 10 | 283 ~+ |
| Female | 1.99 | 1 | NC* | Female | 2.68 | 5 | 186 |
| Total | 7.16 | 3 | NC* | Total | 6.21 | 15 | 241 ~+ |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 1.54 | 1 | NC* | Male | 1.05 | 0 | NC* |
| Female | 1.28 | 3 | NC* | Female | 0.98 | 2 | NC* |
| Total | 2.82 | 4 | NC* | Total | 2.03 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.25 | 0 | NC* | Male | 4.00 | 2 | NC* |
| Female | 32.12 | 21 | 65 #- | Female | 3.70 | 4 | NC* |
| Total | 32.37 | 21 | 65 #- | Total | 7.70 | 6 | 78 |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 3.23 | 1 | NC* |
| Female | 1.52 | 1 | NC* | Female | 1.61 | 2 | NC* |
| | | | | Total | 4.84 | 3 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 12.95 | 5 | 39 #- | | | | |
| Female | 13.02 | 12 | 92 | Female | 3.64 | 3 | NC* |
| Total | 25.97 | 17 | 65 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.92 | 0 | NC* | Male | 2.31 | 0 | NC* |
| Female | 0.62 | 0 | NC* | Female | 2.53 | 2 | NC* |
| Total | 2.53 | 0 | NC* | Total | 4.84 | 2 | NC* |
| Hodgkin's Disease (| | · · | | <u>Prostate</u> | | | |
| Male | 0.60 | 0 | NC* | Male | 33.85 | 26 | 77 |
| Female | 0.50 | 0 | NC* | | | | |
| Total | 1.10 | 0 | NC* | | | | |
| Kidney & Renal Pelv | | | | <u>Stomach</u> | | | |
| Male | 3.08 | 1 | NC* | Male | 2.26 | 3 | NC* |
| Female | 1.91 | 2 | NC* | Female | 1.45 | 1 | NC* |
| Total | 4.99 | 3 | NC* | Total | 3.70 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.71 | 1 | NC* | Male | 0.80 | 1 | NC* |

| Female | 0.43 | 0 | NC* | | | | |
|-----------------------|---------------|----|-----|---------------------|---------------------|-----|-------|
| Total | 2.15 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.45 | 2 | NC* | Male | 0.64 | 0 | NC* |
| Female | 2.07 | 2 | NC* | Female | 1.73 | 1 | NC* |
| Total | 4.52 | 4 | NC* | Total | 2.37 | 1 | NC* |
| Liver and Intrahepati | ic Bile Ducts | | | Uteri, Corpus and L | <u> Iterus, NOS</u> | | |
| Male | 1.33 | 0 | NC* | | | | |
| Female | 0.55 | 0 | NC* | Female | 6.20 | 11 | 177 |
| Total | 1.88 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 16.52 | 12 | 73 | Male | 105.97 | 70 | 66 ^- |
| Female | 13.67 | 11 | 80 | Female | 101.82 | 87 | 85 |
| Total | 30.19 | 23 | 76 | Total | 207.79 | 157 | 76 ^- |

TownsendExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Ехр</u> | <u>Obs</u> | SIR |
|----------------------|----------------|------------|------------|---------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 3.94 | 6 | 152 | Male | 3.56 | 3 | NC* |
| Female | 1.39 | 1 | NC* | Female | 2.87 | 2 | NC* |
| Total | 5.34 | 7 | 131 | Total | 6.43 | 5 | 78 |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 1.72 | 4 | NC* | Male | 0.88 | 0 | NC* |
| Female | 1.37 | 1 | NC* | Female | 0.75 | 3 | NC* |
| Total | 3.09 | 5 | 162 | Total | 1.64 | 3 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Ly | mphoma | | |
| Male | 0.21 | 0 | NC* | Male | 3.87 | 0 | NC* |
| Female | 30.95 | 31 | 100 | Female | 3.15 | 3 | NC* |
| Total | 31.16 | 31 | 99 | Total | 7.01 | 3 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>nx</u> | | |
| | | | | Male | 3.27 | 2 | NC* |
| Female | 1.90 | 0 | NC* | Female | 1.41 | 4 | NC* |
| | | | | Total | 4.68 | 6 | 128 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.17 | 5 | 49 | | | | |
| Female | 9.09 | 7 | 77 | Female | 3.59 | 7 | 195 |
| Total | 19.26 | 12 | 62 | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.68 | 0 | NC* | Male | 1.92 | 1 | NC* |
| Female | 0.43 | 0 | NC* | Female | 1.74 | 1 | NC* |
| Total | 2.11 | 0 | NC* | Total | 3.66 | 2 | NC* |
| Hodgkin's Disease (F | lodgkin Lympho | oma) | | <u>Prostate</u> | | | |
| Male | 0.85 | 0 | NC* | Male | 28.14 | 35 | 124 |
| Female | 0.73 | 0 | NC* | | | | |
| Total | 1.58 | 0 | NC* | | | | |
| Kidney & Renal Pelv | <u>is</u> | | | <u>Stomach</u> | | | |

| Male | 2.93 | 7 | 239 | Male | 1.83 | 1 | NC* |
|----------------------|---------------|----|-----|---------------------|---------------------|-----|-----|
| Female | 1.68 | 0 | NC* | Female | 0.98 | 1 | NC* |
| Total | 4.61 | 7 | 152 | Total | 2.82 | 2 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.60 | 0 | NC* | Male | 1.32 | 0 | NC* |
| Female | 0.39 | 0 | NC* | | | | |
| Total | 1.99 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.39 | 1 | NC* | Male | 0.80 | 1 | NC* |
| Female | 1.85 | 0 | NC* | Female | 2.42 | 5 | 207 |
| Total | 4.23 | 1 | NC* | Total | 3.21 | 6 | 187 |
| Liver and Intrahepat | ic Bile Ducts | | | Uteri, Corpus and L | <u> Iterus, NOS</u> | | |
| Male | 1.27 | 1 | NC* | | | | |
| Female | 0.41 | 0 | NC* | Female | 5.81 | 9 | 155 |
| Total | 1.67 | 1 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 13.36 | 8 | 60 | Male | 91.70 | 76 | 83 |
| Female | 11.16 | 8 | 72 | Female | 90.00 | 90 | 100 |
| Total | 24.53 | 16 | 65 | Total | 181.70 | 166 | 91 |

TruroExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------|------------|------------|--------|----------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 2.05 | 4 | NC* | Male | 1.27 | 0 | NC* |
| Female | 0.59 | 1 | NC* | Female | 0.79 | 2 | NC* |
| Total | 2.64 | 5 | 189 | Total | 2.05 | 2 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.52 | 2 | NC* | Male | 0.40 | 0 | NC* |
| Female | 0.38 | 1 | NC* | Female | 0.30 | 0 | NC* |
| Total | 0.90 | 3 | NC* | Total | 0.70 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lyn | nphoma | | |
| Male | 0.09 | 0 | NC* | Male | 1.47 | 1 | NC* |
| Female | 9.65 | 19 | 197 #+ | Female | 1.14 | 1 | NC* |
| Total | 9.75 | 19 | 195 #+ | Total | 2.61 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyr | <u>nx</u> | | |
| | | | | Male | 1.12 | 2 | NC* |
| Female | 0.44 | 0 | NC* | Female | 0.48 | 0 | NC* |
| | | | | Total | 1.61 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 5.05 | 5 | 99 | | | | |
| Female | 3.89 | 4 | NC* | Female | 1.09 | 1 | NC* |
| Total | 8.93 | 9 | 101 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.70 | 0 | NC* | Male | 0.88 | 1 | NC* |
| Female | 0.18 | 0 | NC* | Female | 0.76 | 4 | NC* |
| Total | 0.89 | 0 | NC* | Total | 1.65 | 5 | 304 |

| Hodgkin's Disease (| Hodgkin Lymphor | <u>na)</u> | | <u>Prostate</u> | | | |
|----------------------|-----------------|------------|-----|---------------------|-------------|----|--------|
| Male | 0.18 | 0 | NC* | Male | 12.42 | 14 | 113 |
| Female | 0.14 | 2 | NC* | | | | |
| Total | 0.32 | 2 | NC* | | | | |
| Kidney & Renal Pelv | <u>/is</u> | | | <u>Stomach</u> | | | |
| Male | 1.12 | 0 | NC* | Male | 0.88 | 0 | NC* |
| Female | 0.59 | 1 | NC* | Female | 0.41 | 0 | NC* |
| Total | 1.71 | 1 | NC* | Total | 1.28 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.61 | 0 | NC* | Male | 0.23 | 0 | NC* |
| Female | 0.14 | 0 | NC* | | | | |
| Total | 0.75 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.90 | 1 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.58 | 0 | NC* | Female | 0.50 | 0 | NC* |
| Total | 1.49 | 1 | NC* | Total | 0.70 | 0 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and U | Iterus, NOS | | |
| Male | 0.48 | 0 | NC* | | | | |
| Female | 0.17 | 0 | NC* | Female | 1.90 | 4 | NC* |
| Total | 0.65 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 6.28 | 6 | 96 | Male | 39.46 | 42 | 106 |
| Female | 4.38 | 3 | NC* | Female | 30.70 | 45 | 147 #+ |
| Total | 10.66 | 9 | 84 | Total | 70.16 | 87 | 124 |

Tyngsborough Expected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | Ехр | Obs | SIR | | Ехр | <u>Obs</u> | SIR |
|---------------------|-------------|-----|-----|----------------------|---------------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.21 | 3 | NC* | Male | 3.77 | 2 | NC* |
| Female | 1.49 | 1 | NC* | Female | 3.01 | 4 | NC* |
| Total | 5.70 | 4 | NC* | Total | 6.78 | 6 | 89 |
| Brain and Other Ner | vous System | | | Multiple Myeloma | | | |
| Male | 1.87 | 3 | NC* | Male | 0.94 | 0 | NC* |
| Female | 1.45 | 1 | NC* | Female | 0.80 | 0 | NC* |
| Total | 3.32 | 4 | NC* | Total | 1.74 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lym | <u>iphoma</u> | | |
| Male | 0.23 | 0 | NC* | Male | 4.11 | 2 | NC* |
| Female | 32.41 | 27 | 83 | Female | 3.36 | 9 | 268 #+ |
| Total | 32.64 | 27 | 83 | Total | 7.47 | 11 | 147 |
| Cervix Uteri | | | | Oral Cavity & Pharyn | <u>IX</u> | | |
| | | | | Male | 3.44 | 5 | 145 |
| Female | 1.98 | 1 | NC* | Female | 1.49 | 1 | NC* |
| | | | | Total | 4.92 | 6 | 122 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.91 | 10 | 92 | | | | |
| Female | 9.67 | 12 | 124 | Female | 3.77 | 7 | 186 |

| Total | 20.58 | 22 | 107 | | | | |
|----------------------|----------------|------------|-----|---------------------|-------------|-----|-----|
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 1.80 | 2 | NC* | Male | 2.04 | 0 | NC* |
| Female | 0.46 | 0 | NC* | Female | 1.87 | 1 | NC* |
| Total | 2.26 | 2 | NC* | Total | 3.91 | 1 | NC* |
| Hodgkin's Disease (| Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 0.93 | 1 | NC* | Male | 30.96 | 30 | 97 |
| Female | 0.77 | 0 | NC* | | | | |
| Total | 1.70 | 1 | NC* | | | | |
| Kidney & Renal Pelv | <u>vis</u> | | | Stomach | | | |
| Male | 3.12 | 2 | NC* | Male | 1.92 | 4 | NC* |
| Female | 1.78 | 1 | NC* | Female | 1.04 | 0 | NC* |
| Total | 4.90 | 3 | NC* | Total | 2.96 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.72 | 3 | NC* | Male | 1.45 | 1 | NC* |
| Female | 0.41 | 2 | NC* | | | | |
| Total | 2.13 | 5 | 235 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.56 | 2 | NC* | Male | 0.85 | 2 | NC* |
| Female | 1.96 | 3 | NC* | Female | 2.53 | 3 | NC* |
| Total | 4.51 | 5 | 111 | Total | 3.38 | 5 | 148 |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and L | Jterus, NOS | | |
| Male | 1.35 | 2 | NC* | | | | |
| Female | 0.43 | 2 | NC* | Female | 6.09 | 4 | NC* |
| Total | 1.78 | 4 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 14.65 | 15 | 102 | Male | 99.19 | 95 | 96 |
| Female | 11.98 | 12 | 100 | Female | 95.03 | 92 | 97 |
| Total | 26.63 | 27 | 101 | Total | 194.22 | 187 | 96 |

TyringhamExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------------|------------|------------|-----|----------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.47 | 0 | NC* | Male | 0.30 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.16 | 0 | NC* |
| Total | 0.58 | 0 | NC* | Total | 0.47 | 0 | NC* |
| Brain and Other Nerv | ous System | | | Multiple Myeloma | | | |
| Male | 0.13 | 0 | NC* | Male | 0.09 | 0 | NC* |
| Female | 0.08 | 0 | NC* | Female | 0.06 | 0 | NC* |
| Total | 0.20 | 0 | NC* | Total | 0.15 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lym | <u>nphoma</u> | | |
| Male | 0.02 | 0 | NC* | Male | 0.35 | 0 | NC* |
| Female | 2.08 | 0 | NC* | Female | 0.22 | 0 | NC* |
| Total | 2.10 | 0 | NC* | Total | 0.57 | 0 | NC* |
| Cervix Uteri | | | | Oral Cavity & Pharyn | <u>IX</u> | | |
| | | | | Male | 0.29 | 0 | NC* |

| Female | 0.09 | 0 | NC* | Female | 0.10 | 0 | NC* |
|-------------------|--------------------|------------|-----|---------------------|------------|---|-------|
| | | | | Total | 0.39 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.18 | 1 | NC* | | | | |
| Female | 0.73 | 0 | NC* | Female | 0.23 | 0 | NC* |
| Total | 1.91 | 1 | NC* | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | |
| Male | 0.17 | 0 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.03 | 0 | NC* | Female | 0.14 | 0 | NC* |
| Total | 0.21 | 0 | NC* | Total | 0.35 | 0 | NC* |
| Hodgkin's Diseas | e (Hodgkin Lymphon | <u>na)</u> | | <u>Prostate</u> | | | |
| Male | 0.04 | 0 | NC* | Male | 3.13 | 3 | NC* |
| Female | 0.03 | 0 | NC* | | | | |
| Total | 0.07 | 0 | NC* | | | | |
| Kidney & Renal P | <u>elvis</u> | | | Stomach . | | | |
| Male | 0.27 | 0 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.12 | 0 | NC* | Female | 0.08 | 0 | NC* |
| Total | 0.39 | 0 | NC* | Total | 0.28 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.15 | 0 | NC* | Male | 0.04 | 0 | NC* |
| Female | 0.03 | 0 | NC* | | | | |
| Total | 0.18 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.21 | 0 | NC* | Male | 0.05 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.11 | 0 | NC* |
| Total | 0.32 | 0 | NC* | Total | 0.16 | 0 | NC* |
| Liver and Intrahe | patic Bile Ducts | | | Uteri, Corpus and U | terus, NOS | | |
| Male | 0.12 | 0 | NC* | | | | |
| Female | 0.03 | 0 | NC* | Female | 0.42 | 0 | NC* |
| Total | 0.15 | 0 | NC* | | | | |
| Lung and Bronch | <u>us</u> | | | All Sites / Types | | | |
| Male | 1.50 | 0 | NC* | Male | 9.54 | 5 | 52 |
| Female | 0.89 | 0 | NC* | Female | 6.28 | 1 | NC* |
| Total | 2.39 | 0 | NC* | Total | 15.82 | 6 | 38 ~- |

UptonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|-----------------------|------------|--------------------------|------------|------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 3.04 | 1 | NC* | Male | 2.38 | 3 | NC* |
| Female | 1.13 | 0 | NC* | Female | 1.80 | 2 | NC* |
| Total | 4.16 | 1 | NC* | Total | 4.18 | 5 | 120 |
| Brain and Other Nerve | ous System | | | Multiple Myeloma | | | |
| Male | 1.10 | 2 | NC* | Male | 0.65 | 0 | NC* |
| Female | 0.89 | 2 | NC* | Female | 0.57 | 1 | NC* |
| Total | 1.99 | 4 | NC* | Total | 1.22 | 1 | NC* |
| <u>Breast</u> | | Non-Hodgkin('s) Lymphoma | | | | | |

| Male | 0.16 | 0 | NC* | Male | 2.63 | 1 | NC* |
|-----------------------------------|----------------|------------|-------------------------------|---------------------|------------|-----|-----|
| Female | 20.32 | 20 | 98 | Female | 2.29 | 1 | NC* |
| Total | 20.48 | 20 | 98 | Total | 4.92 | 2 | NC* |
| Cervix Uteri | | | | Oral Cavity & Phary | <u>/nx</u> | | |
| | | | | Male | 2.18 | 3 | NC* |
| Female | 1.11 | 0 | NC* | Female | 0.98 | 1 | NC* |
| | | | | Total | 3.16 | 4 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 7.74 | 8 | 103 | | | | |
| Female | 7.39 | 14 | 189 #+ | Female | 2.34 | 2 | NC* |
| Total | 15.13 | 22 | 145 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.21 | 1 | NC* | Male | 1.41 | 1 | NC* |
| Female | 0.35 | 0 | NC* | Female | 1.43 | 0 | NC* |
| Total | 1.56 | 1 | NC* | Total | 2.84 | 1 | NC* |
| Hodgkin's Disease (| Hodgkin Lympho | <u>ma)</u> | | <u>Prostate</u> | | | |
| Male | 0.49 | 1 | NC* | Male | 21.22 | 16 | 75 |
| Female | 0.41 | 1 | NC* | | | | |
| Total | 0.90 | 2 | NC* | | | | |
| Kidney & Renal Pelv | <u>/is</u> | | | <u>Stomach</u> | | | |
| Male | 2.03 | 1 | NC* | Male | 1.35 | 2 | NC* |
| Female | 1.18 | 1 | NC* | Female | 0.80 | 1 | NC* |
| Total | 3.21 | 2 | NC* | Total | 2.14 | 3 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.12 | 0 | NC* | Male | 0.72 | 1 | NC* |
| Female | 0.27 | 0 | NC* | | | | |
| Total | 1.39 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 1.62 | 1 | NC* | Male | 0.48 | 0 | NC* |
| Female | 1.30 | 1 | NC* | Female | 1.34 | 1 | NC* |
| Total | 2.92 | 2 | NC* | Total | 1.83 | 1 | NC* |
| Liver and Intrahepatic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 0.88 | 0 | NC* | | | | |
| Female | 0.32 | 1 | NC* | Female | 3.87 | 2 | NC* |
| Total | 1.20 | 1 | NC* | | | | |
| Lung and Bronchus | i | | | All Sites / Types | | | |
| Male | 10.20 | 7 | 69 | Male | 66.85 | 52 | 78 |
| Female | 8.29 | 8 | 97 | Female | 62.85 | 61 | 97 |
| Total | 18.48 | 15 | 81 | Total | 129.70 | 113 | 87 |
| | | | | | | | |

UxbridgeExpected and Observed Case Counts, with Standardized Incidence Ratios, 1996 – 2000

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Exp</u> | <u>Obs</u> | SIR |
|------------------|------------|------------|-----|------------------|------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 6.90 | 7 | 101 | Male | 5.16 | 2 | NC* |
| Female | 2.62 | 2 | NC* | Female | 4.18 | 0 | NC* |
| Total | 9.53 | 9 | 94 | Total | 9.33 | 2 | NC* |

| Brain and Other Nervous System | | | | Multiple Myeloma | | | | |
|--------------------------------------|-----------------------------------|----|-------------------|-------------------------------|--------|-----|-----|--|
| Male | 2.40 | 3 | NC* | Male | 1.43 | 1 | NC* | |
| Female | 2.04 | 4 | NC* | Female | 1.31 | 1 | NC* | |
| Total | 4.44 | 7 | 158 | Total | 2.74 | 2 | NC* | |
| <u>Breast</u> | | | | Non-Hodgkin('s) Lymphoma | | | | |
| Male | 0.35 | 0 | NC* | Male | 5.84 | 8 | 137 | |
| Female | 45.79 | 34 | 74 | Female | 5.29 | 2 | NC* | |
| Total | 46.13 | 34 | 74 | Total | 11.13 | 10 | 90 | |
| Cervix Uteri | | | | Oral Cavity & Pharynx | | | | |
| | | | | Male | 4.57 | 5 | 109 | |
| Female | 2.59 | 2 | NC* | Female | 2.24 | 2 | NC* | |
| | | | | Total | 6.80 | 7 | 103 | |
| Colon / Rectum | | | | <u>Ovary</u> | | | | |
| Male | 17.41 | 11 | 63 | | | | | |
| Female | 17.16 | 20 | 117 | Female | 5.34 | 5 | 94 | |
| Total | 34.57 | 31 | 90 | | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | | |
| Male | 2.60 | 1 | NC* | Male | 3.13 | 2 | NC* | |
| Female | 0.81 | 0 | NC* | Female | 3.33 | 6 | 180 | |
| Total | 3.41 | 1 | NC* | Total | 6.46 | 8 | 124 | |
| Hodgkin's Disease (Hodgkin Lymphoma) | | | <u>Prostate</u> | | | | | |
| Male | 1.11 | 0 | NC* | Male | 45.15 | 38 | 84 | |
| Female | 1.00 | 0 | NC* | | | | | |
| Total | 2.12 | 0 | NC* | | | | | |
| Kidney & Renal Pelv | <u>ris</u> | | | Stomach | | | | |
| Male | 4.35 | 4 | NC* | Male | 3.05 | 4 | NC* | |
| Female | 2.69 | 1 | NC* | Female | 1.88 | 3 | NC* | |
| Total | 7.04 | 5 | 71 | Total | 4.93 | 7 | 142 | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 2.35 | 0 | NC* | Male | 1.73 | 3 | NC* | |
| Female | 0.60 | 1 | NC* | | | | | |
| Total | 2.95 | 1 | NC* | | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | | |
| Male | 3.61 | 6 | 166 | Male | 1.05 | 0 | NC* | |
| Female | 2.98 | 1 | NC* | Female | 3.19 | 2 | NC* | |
| Total | 6.60 | 7 | 106 | Total | 4.24 | 2 | NC* | |
| Liver and Intrahepat | Liver and Intrahepatic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 1.87 | 1 | NC* | | | | | |
| Female | 0.74 | 0 | NC* | Female | 8.60 | 10 | 116 | |
| Total | 2.61 | 1 | NC* | | | | | |
| Lung and Bronchus | | | All Sites / Types | | | | | |
| Male | 22.25 | 28 | 126 | Male | 145.97 | 138 | 95 | |
| Female | 18.79 | 20 | 106 | Female | 143.56 | 125 | 87 | |
| Total | 41.05 | 48 | 117 | Total | 289.54 | 263 | 91 | |
| | | | | | | | | |